rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-32-54rsp-3512Research ArticleПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕPROGRESS IN RHEUMATOLOGY IN THE XXI CENTURYПандемия коронавирусной болезни 2019 (COVID-19) и аутоиммунные ревматические заболевания: итоги и перспективыCoronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospectshttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

Насонов Евгений Львович – д.м.н., профессор, академик РАН, научный руководитель;

профессор кафедры внутренних, профессиональных болезней и ревматологии;

115522, Москва, Каширское шоссе, 34а;

119991, Москва, ул. Трубецкая, 8, стр. 2

Evgeny L. Nasonov

115522, Moscow, Kashirskoye Highway, 34A;

119991, Moscow, Trubetskaya str., 8, building 2

nasonov@irramn.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation2024290220246213254Copyright © Насонов Е.Л., 20242024Насонов Е.Л.Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3512

Пандемия коронавирусной болезни 2019 (COVID-19, coronavirus disease 2019), этиологически связанной с вирусом SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), привлекла внимание к новым клиническим и фундаментальным проблемам иммунопатологии заболеваний человека, связанными с вирусиндуцированным аутоиммунитетом и аутовоспалением. Положение о том, что «опыт, накопленный в ревматологии в процессе изучения патогенетических механизмов и фармакотерапии иммуновоспалительных ревматических заболеваний как наиболее частых и тяжелых форм аутоиммунной и аутовоспалительной патологии человека, будет востребован для расшифровки природы патологических процессов, лежащих в основе COVID-19 и разработки подходов к эффективной фармакотерапии», нашло подтверждение в многочисленных исследованиях, проведенных в течение последующих 3 лет в разгар пандемии COVID-19. Основное внимание будет уделено критическому анализу данных, касающихся роли аутоиммунного воспаления, составляющего основу патогенеза иммуновоспалительных ревматических заболеваний в контексте иммунопатологии COVID-19.

The pandemic of coronavirus disease 2019 (COVID-19), etiologically related to the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2), has drawn attention to new clinical and fundamental problems in the immunopathology of human diseases associated with virus-induced autoimmunity and autoinflammation. The provision that “the experience gained in rheumatology in the process of studying the pathogenetic mechanisms and pharmacotherapy of immunoinflammatory rheumatic diseases as the most common and severe forms of autoimmune and autoinflammatory pathology in humans will be in demand for deciphering the nature of the pathological processes underlying COVID-19 and developing approaches to effective pharmacotherapy” was confirmed in numerous studies conducted over the next 3 years in the midst of the COVID-19 pandemic. The main focus will be on a critical analysis of data regarding the role of autoimmune inflammation, which forms the basis of the pathogenesis of immune-mediated rheumatic diseases in the context of the immunopathology of COVID-19.

COVID-19иммуновоспалительные ревматические заболеванияаутоантителаCOVID-19immune-mediated rheumatic diseasesautoantibodiesReferencesНасонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-132. doi: 10.14412/1995-4484-2020-123-132НNasonov EL. Coronavirus disease 2019 (COVID-19): A rheumatologist’s thoughts. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(2):123-132 (In Russ.) doi: 10.14412/1995-4484-2020-123-132Schett G, Sticherling M, Neurath MF. COVID-19: Risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271-272. doi: 10.1038/s41577-020-0312-7Schett G, Sticherling M, Neurath MF. COVID-19: Risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271-272. doi: 10.1038/s41577-020-0312-7Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465-470. doi: 10.1038/s41584-020-0451-zSchett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465-470. doi: 10.1038/s41584-020-0451-zНасонов ЕЛ. Современная концепция аутоиммунитета в ревматологии. Научно-практическая ревматология. 2023;61(4):397-420. doi: 10.47360/1995-4484-2023-397-420Nasonov EL. Modern concept of autoimmunity in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(4):397-420 (In Russ.) doi: 10.47360/1995-4484-2023-397-420Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023;19(8):509-524. doi: 10.1038/s41581-023-00720-1Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023;19(8):509-524. doi: 10.1038/s41581-023-00720-1Sher EK, Ćosović A, Džidić-Krivić A, Farhat EK, Pinjić E, Sher F. COVID-19: A triggering factor of autoimmune and multi-inflammatory diseases. Life Sci. 2023;319:121531. doi: 10.1016/j.lfs.2023.121531Sher EK, Ćosović A, Džidić-Krivić A, Farhat EK, Pinjić E, Sher F. COVID-19: A triggering factor of autoimmune and multi-inflammatory diseases. Life Sci. 2023;319:121531. doi: 10.1016/j.lfs.2023.121531Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4):102792. doi: 10.1016/j.autrev.2021.102792Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4):102792. doi: 10.1016/j.autrev.2021.102792Halpert G, Shoenfeld Y. SARS-CoV-2, the autoimmune virus. Autoimmun Rev. 2020;19(12):102695. doi: 10.1016/j.autrev.2020.102695Halpert G, Shoenfeld Y. SARS-CoV-2, the autoimmune virus. Autoimmun Rev. 2020;19(12):102695. doi: 10.1016/j.autrev.2020.102695Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-162. doi: 10.1097/BOR.0000000000000776Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-162. doi: 10.1097/BOR.0000000000000776Knight JS, Caricchio R, Casanova JL, Combes AJ, Diamond B, Fox SE, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131(24):e154886. doi: 10.1172/JCI154886Knight JS, Caricchio R, Casanova JL, Combes AJ, Diamond B, Fox SE, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131(24):e154886. doi: 10.1172/JCI154886Rojas M, Herrán M, Ramírez-Santana C, Leung PSC, Anaya JM, Ridgway WM, et al. Molecular mimicry and autoimmunity in the time of COVID-19. J Autoimmun. 2023;139:103070. doi: 10.1016/j.jaut.2023.103070Rojas M, Herrán M, Ramírez-Santana C, Leung PSC, Anaya JM, Ridgway WM, et al. Molecular mimicry and autoimmunity in the time of COVID-19. J Autoimmun. 2023;139:103070. doi: 10.1016/j.jaut.2023.103070Vojdani A, Vojdani E, Saidara E, Maes M. Persistent SARSCoV-2 infection, EBV, HHV-6 and other factors may contribute to inflammation and autoimmunity in long COVID. Viruses. 2023;15(2):400. doi: 10.3390/v15020400Vojdani A, Vojdani E, Saidara E, Maes M. Persistent SARSCoV-2 infection, EBV, HHV-6 and other factors may contribute to inflammation and autoimmunity in long COVID. Viruses. 2023;15(2):400. doi: 10.3390/v15020400Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ, Лила АМ, Ананьева ЛП, Лисицина ТА, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353-367. doi: 10.47360/1995-4484-2020-353-367Nasonov EL, Beketova TV, Reshetnyak TM, Lila AM, Ananieva LP, Lisitsyna TA, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: At the crossroads of thromboinflammation and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(4):353-367 (In Russ.) doi: 10.47360/1995-4484-2020-353-367Nasonov EL, Samsonov MY, Lila AM. Coronavirus infection 2019 (COVID-19) and autoimmunity. Her Russ Acad Sci. 2022; 92(4):398-403. doi: 10.1134/S1019331622040062Nasonov EL, Samsonov MY, Lila AM. Coronavirus infection 2019 (COVID-19) and autoimmunity. Her Russ Acad Sci. 2022; 92(4):398-403. doi: 10.1134/S1019331622040062Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkő S, Szűcs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-595. doi: 10.1038/s41584-021-00652-9Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkő S, Szűcs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-595. doi: 10.1038/s41584-021-00652-9Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: A comprehensive update. J Intern Med. 2015;278(4):369-395. doi: 10.1111/joim.12395Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: A comprehensive update. J Intern Med. 2015;278(4):369-395. doi: 10.1111/joim.12395Nissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, et al. The role of antirheumatics in patients with COVID-19. Lancet Rheumatol. 2021;3(6):e447-e459. doi: 10.1016/S2665-9913(21)00062-XNissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, et al. The role of antirheumatics in patients with COVID-19. Lancet Rheumatol. 2021;3(6):e447-e459. doi: 10.1016/S2665-9913(21)00062-Xvan de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39-50. doi: 10.1038/s41591-021-01643-9van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39-50. doi: 10.1038/s41591-021-01643-9Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: Progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449-475. doi: 10.1038/s41573-023-00672-yLi G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: Progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449-475. doi: 10.1038/s41573-023-00672-yBerlin DA, Gulick RM, Martinez FJ. Severe COVID-19. N Engl J Med. 2020;383(25):2451-2460. doi: 10.1056/NEJMcp2009575Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. N Engl J Med. 2020;383(25):2451-2460. doi: 10.1056/NEJMcp2009575Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, et al. COVID-19 in patients with autoimmune diseases: Characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford). 2021;60(SI):SI37-SI50. doi: 10.1093/rheumatology/keab250Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, et al. COVID-19 in patients with autoimmune diseases: Characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford). 2021;60(SI):SI37-SI50. doi: 10.1093/rheumatology/keab250Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122-1127. doi: 10.1126/science.abm8108Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122-1127. doi: 10.1126/science.abm8108Mohandas S, Jagannathan P, Henrich TJ, Sherif ZA, Bime C, Quinlan E, et al.; RECOVER Mechanistic Pathways Task Force. Immune mechanisms underlying COVID-19 pathology and postacute sequelae of SARS-CoV-2 infection (PASC). Elife. 2023;12:e86014. doi: 10.7554/eLife.86014Mohandas S, Jagannathan P, Henrich TJ, Sherif ZA, Bime C, Quinlan E, et al.; RECOVER Mechanistic Pathways Task Force. Immune mechanisms underlying COVID-19 pathology and postacute sequelae of SARS-CoV-2 infection (PASC). Elife. 2023;12:e86014. doi: 10.7554/eLife.86014Dey A, Vaishak K, Deka D, Radhakrishnan AK, Paul S, Shanmugam P, et al. Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: An updated review. Infection. 2023;51(6):1603-1618. doi: 10.1007/s15010-023-02017-8Dey A, Vaishak K, Deka D, Radhakrishnan AK, Paul S, Shanmugam P, et al. Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: An updated review. Infection. 2023;51(6):1603-1618. doi: 10.1007/s15010-023-02017-8Zhang F, Lau RI, Liu Q, Su Q, Chan FKL, Ng SC. Gut microbiota in COVID-19: Key microbial changes, potential mechanisms and clinical applications. Nat Rev Gastroenterol Hepatol. 2023;20(5):323-337. doi: 10.1038/s41575-022-00698-4Zhang F, Lau RI, Liu Q, Su Q, Chan FKL, Ng SC. Gut microbiota in COVID-19: Key microbial changes, potential mechanisms and clinical applications. Nat Rev Gastroenterol Hepatol. 2023;20(5):323-337. doi: 10.1038/s41575-022-00698-4Zazzara MB, Bellieni A, Calvani R, Coelho-Junior HJ, Picca A, Marzetti E. Inflammaging at the time of COVID-19. Clin Geriatr Med. 2022;38(3):473-481. doi: 10.1016/j.cger.2022.03.003Zazzara MB, Bellieni A, Calvani R, Coelho-Junior HJ, Picca A, Marzetti E. Inflammaging at the time of COVID-19. Clin Geriatr Med. 2022;38(3):473-481. doi: 10.1016/j.cger.2022.03.003Netea MG, Ziogas A, Benn CS, Giamarellos-Bourboulis EJ, Joosten LAB, Arditi M, et al. The role of trained immunity in COVID-19: Lessons for the next pandemic. Cell Host Microbe. 2023;31(6):890-901. doi: 10.1016/j.chom.2023.05.004Netea MG, Ziogas A, Benn CS, Giamarellos-Bourboulis EJ, Joosten LAB, Arditi M, et al. The role of trained immunity in COVID-19: Lessons for the next pandemic. Cell Host Microbe. 2023;31(6):890-901. doi: 10.1016/j.chom.2023.05.004Suárez-Reyes A, Villegas-Valverde CA. Implications of low-grade inflammation in SARS-CoV-2 immunopathology. MEDICC Rev. 2021;23(2):42. doi: 10.37757/MR2021.V23.N2.4Suárez-Reyes A, Villegas-Valverde CA. Implications of low-grade inflammation in SARS-CoV-2 immunopathology. MEDICC Rev. 2021;23(2):42. doi: 10.37757/MR2021.V23.N2.4Kim JYH, Ragusa M, Tortosa F, Torres A, Gresh L, MéndezRico JA, et al. Viral reactivations and co-infections in COVID-19 patients: A systematic review. BMC Infect Dis. 2023;23(1):259. doi: 10.1186/s12879-023-08117-yKim JYH, Ragusa M, Tortosa F, Torres A, Gresh L, MéndezRico JA, et al. Viral reactivations and co-infections in COVID-19 patients: A systematic review. BMC Infect Dis. 2023;23(1):259. doi: 10.1186/s12879-023-08117-yFajgenbaum DC, June CH, Cytokine storm. N Engl J Med. 2020;383:2255-2273. doi: 10.1056/NEJMra2026131Fajgenbaum DC, June CH, Cytokine storm. N Engl J Med. 2020;383:2255-2273. doi: 10.1056/NEJMra2026131Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276-e288. doi: 10.1016/S1473-3099(20)30651-4Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276-e288. doi: 10.1016/S1473-3099(20)30651-4Каледа МИ, Никишина ИП, Федоров ЕС, Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) у детей: уроки педиатрической ревматологии. Научно-практическая ревматология. 2020;58(5):469-479. doi: 10.47360/1995-4484-2020-469-479Kaleda MI, Nikishina IP, Fedorov ES, Nasonov EL. Coronavirus disease 2019 (COVID-19) in children: Lessons from pediatric rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(5):469-479 (In Russ.) doi: 10.47360/1995-4484-2020-469-479Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: Major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi: 10.1038/s41579-022-00846-2Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: Major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi: 10.1038/s41579-022-00846-2Nalbandian A, Desai AD, Wan EY. Post-COVID-19 condition. Annu Rev Med. 2023;74:55-64. doi: 10.1146/annurevmed-043021-030635Nalbandian A, Desai AD, Wan EY. Post-COVID-19 condition. Annu Rev Med. 2023;74:55-64. doi: 10.1146/annurevmed-043021-030635Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023;23(10):618-634. doi: 10.1038/s41577-023-00904-7Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023;23(10):618-634. doi: 10.1038/s41577-023-00904-7Lammi V, Nakanishi T, Jones SE, Andrews SJ, Karjalainen J, Cortés B, et al. Genome-wide association study of long COVID. medRxiv. 2023.06.29.23292056. doi: 10.1101/2023.06.29.23292056Lammi V, Nakanishi T, Jones SE, Andrews SJ, Karjalainen J, Cortés B, et al. Genome-wide association study of long COVID. medRxiv. 2023.06.29.23292056. doi: 10.1101/2023.06.29.23292056Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi: 10.1038/s41598-021-95565-8Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi: 10.1038/s41598-021-95565-8Legler F, Meyer-Arndt L, Mödl L, Kedor C, Freitag H, Stein E, et al. Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: Results from a prospective observational cohort. EClinicalMedicine. 2023;63:102146. doi: 10.1016/j.eclinm.2023.102146Legler F, Meyer-Arndt L, Mödl L, Kedor C, Freitag H, Stein E, et al. Long-term symptom severity and clinical biomarkers in postCOVID-19/chronic fatigue syndrome: Results from a prospective observational cohort. EClinicalMedicine. 2023;63:102146. doi: 10.1016/j.eclinm.2023.102146Каратеев АЕ, Амирджанова ВН, Насонов ЕЛ, Лила АМ, Алексеева ЛИ, Погожева ЕЮ, и др. «Постковидный синдром»: в центре внимания скелетно-мышечная боль. Научнопрактическая ревматология. 2021;59(3):255-262. doi: 10.47360/1995-4484-2021-255-262Karateev AE, Amirdzhanova VN, Nasonov EL, Lila AM, Alekseeva LI, Pogozheva EYu, et al. “Post-COVID syndrome”: The focus is on musculoskeletal pain. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(3):255-262 (In Russ.) doi: 10.47360/1995-4484-2021-255-262Grainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: Risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022;18(4):191-204. doi: 10.1038/s41584-022-00755-xGrainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: Risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022;18(4):191-204. doi: 10.1038/s41584-022-00755-xZacharias H, Dubey S, Koduri G, D’Cruz D. Rheumatological complications of COVID-19. Autoimmun Rev. 2021;20(9):102883. doi: 10.1016/j.autrev.2021.102883Zacharias H, Dubey S, Koduri G, D’Cruz D. Rheumatological complications of COVID-19. Autoimmun Rev. 2021;20(9):102883. doi: 10.1016/j.autrev.2021.102883Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021;10(12):3592. doi: 10.3390/cells10123592Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021;10(12):3592. doi: 10.3390/cells10123592Ramos-Casals M, Brito-Zerón P, Mariette X. Systemic and organspecific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17(6):315-332. doi:10.1038/s41584-021-00608-zRamos-Casals M, Brito-Zerón P, Mariette X. Systemic and organspecific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17(6):315-332. doi:10.1038/s41584-021-00608-zCiaffi J, Vanni E, Mancarella L, Brusi V, Lisi L, Pignatti F, et al. Post-acute COVID-19 joint pain and new onset of rheumatic musculoskeletal diseases: A systematic review. Diagnostics (Basel). 2023;13(11):1850. doi: 10.3390/diagnostics13111850Ciaffi J, Vanni E, Mancarella L, Brusi V, Lisi L, Pignatti F, et al. Post-acute COVID-19 joint pain and new onset of rheumatic musculoskeletal diseases: A systematic review. Diagnostics (Basel). 2023;13(11):1850. doi: 10.3390/diagnostics13111850Guo M, Liu X, Chen X, Li Q. Insights into new-onset autoimmune diseases after COVID-19 vaccination. Autoimmun Rev. 2023;22(7):103340. doi: 10.1016/j.autrev.2023.103340Guo M, Liu X, Chen X, Li Q. Insights into new-onset autoimmune diseases after COVID-19 vaccination. Autoimmun Rev. 2023;22(7):103340. doi: 10.1016/j.autrev.2023.103340Kouranloo K, Dey M, Elwell H, Nune A. A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19. Rheumatol Int. 2023;43(7):1221-1243. doi: 10.1007/s00296-023-05283-9Kouranloo K, Dey M, Elwell H, Nune A. A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19. Rheumatol Int. 2023;43(7):1221-1243. doi: 10.1007/s00296-023-05283-9Fedorchenko Y, Zimba O. Long COVID in autoimmune rheumatic diseases. Rheumatol Int. 2023;43(7):1197-1207. doi: 10.1007/s00296-023-05319-0Fedorchenko Y, Zimba O. Long COVID in autoimmune rheumatic diseases. Rheumatol Int. 2023;43(7):1197-1207. doi: 10.1007/s00296-023-05319-0Marks M, Marks JL. Viral arthritis. Clin Med (Lond). 2016;16(2):129-134. doi: 10.7861/clinmedicine.16-2-129Marks M, Marks JL. Viral arthritis. Clin Med (Lond). 2016;16(2):129-134. doi: 10.7861/clinmedicine.16-2-129Copley M, Kozminski B, Gentile N, Geyer R, Friedly J. Postacute sequelae of SARS-CoV-2: Musculoskeletal conditions and pain. Phys Med Rehabil Clin N Am. 2023;34(3):585-605. doi: 10.1016/j.pmr.2023.04.008Copley M, Kozminski B, Gentile N, Geyer R, Friedly J. Postacute sequelae of SARS-CoV-2: Musculoskeletal conditions and pain. Phys Med Rehabil Clin N Am. 2023;34(3):585-605. doi: 10.1016/j.pmr.2023.04.008Баймухамедов ЧТ, Ботабекова АК, Досыбаева ГН, Махмудов ША. Ревматоидный артрит и постковидный синдром. Научно-практическая ревматология. 2022;60(3):276-279. doi: 10.47360/1995-4484-2022-276-279Baimukhamedov CT, Botabekova AK, Dossybayeva GN, Makhmudov SA. Rheumatoid arthritis and post-COVID-19 syndrome. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(3):276-279 (In Russ.) doi: 10.47360/1995-4484-2022-276-279Farisogullari B, Pinto AS, Machado PM. COVID-19-associated arthritis: An emerging new entity? RMD Open. 2022;8(2):e002026. doi: 10.1136/rmdopen-2021-002026Farisogullari B, Pinto AS, Machado PM. COVID-19-associated arthritis: An emerging new entity? RMD Open. 2022;8(2):e002026. doi: 10.1136/rmdopen-2021-002026Kocyigit BF, Akyol A. The relationship between COVID-19 and fibromyalgia syndrome: Prevalence, pandemic effects, symptom mechanisms, and COVID-19 vaccines. Clin Rheumatol. 2022; 41(10):3245-3252. doi: 10.1007/s10067-022-06279-9Kocyigit BF, Akyol A. The relationship between COVID-19 and fibromyalgia syndrome: Prevalence, pandemic effects, symptom mechanisms, and COVID-19 vaccines. Clin Rheumatol. 2022; 41(10):3245-3252. doi: 10.1007/s10067-022-06279-9Boekel L, Atiqi S, Leeuw M, Hooijberg F, Besten YR, Wartena R, et al. Post-COVID condition in patients with inflammatory rheumatic diseases: A prospective cohort study in the Netherlands. Lancet Rheumatol. 2023;5(7):e375-e385. doi: 10.1016/S2665-9913(23)00127-3Boekel L, Atiqi S, Leeuw M, Hooijberg F, Besten YR, Wartena R, et al. Post-COVID condition in patients with inflammatory rheumatic diseases: A prospective cohort study in the Netherlands. Lancet Rheumatol. 2023;5(7):e375-e385. doi: 10.1016/S2665-9913(23)00127-3Calabrese LH. Long COVID in inflammatory rheumatic diseases – What’s in a name? Lancet Rheumatol. 2023;5(7):e364-e365. doi: 10.1016/S2665-9913(23)00134-0Calabrese LH. Long COVID in inflammatory rheumatic diseases – What’s in a name? Lancet Rheumatol. 2023;5(7):e364-e365. doi: 10.1016/S2665-9913(23)00134-0Sen P, Ravichandran N, Nune A, Lilleker JB, Agarwal V, Kardes S, et al.; COVAD Study Group. COVID-19 vaccinationrelated adverse events among autoimmune disease patients: Results from the COVAD study. Rheumatology (Oxford). 2022;62(1):65-76. doi: 10.1093/rheumatology/keac305Sen P, Ravichandran N, Nune A, Lilleker JB, Agarwal V, Kardes S, et al.; COVAD Study Group. COVID-19 vaccinationrelated adverse events among autoimmune disease patients: Results from the COVAD study. Rheumatology (Oxford). 2022;62(1):65-76. doi: 10.1093/rheumatology/keac305Chang R, Yen-Ting Chen T, Wang SI, Hung YM, Chen HY, Wei CJ. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023;56:101783. doi: 10.1016/j.eclinm.2022.101783Chang R, Yen-Ting Chen T, Wang SI, Hung YM, Chen HY, Wei CJ. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023;56:101783. doi: 10.1016/j.eclinm.2022.101783Tesch F, Ehm F, Vivirito A, Wende D, Batram M, Loser F, et al. Incident autoimmune diseases in association with SARSCoV-2 infection: A matched cohort study. Clin Rheumatol. 2023;42(10):2905-2914. doi: 10.1007/s10067-023-06670-0Tesch F, Ehm F, Vivirito A, Wende D, Batram M, Loser F, et al. Incident autoimmune diseases in association with SARSCoV-2 infection: A matched cohort study. Clin Rheumatol. 2023;42(10):2905-2914. doi: 10.1007/s10067-023-06670-0Syed U, Subramanian A, Wraith DC, Lord JM, McGee K, Ghokale K, et al. Incidence of immune-mediated inflammatory diseases following COVID-19: A matched cohort study in UK primary care. BMC Med. 2023;21(1):363. doi: 10.1186/s12916-023-03049-5Syed U, Subramanian A, Wraith DC, Lord JM, McGee K, Ghokale K, et al. Incidence of immune-mediated inflammatory diseases following COVID-19: A matched cohort study in UK primary care. BMC Med. 2023;21(1):363. doi: 10.1186/s12916-023-03049-5Peng K, Li X, Yang D, Chan SCW, Zhou J, Wan EYF, et al. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: A population-based cohort study. EClinicalMedicine. 2023;63:102154. doi: 10.1016/j.eclinm.2023.102154Peng K, Li X, Yang D, Chan SCW, Zhou J, Wan EYF, et al. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: A population-based cohort study. EClinicalMedicine. 2023;63:102154. doi: 10.1016/j.eclinm.2023.102154Lim SH, Ju HJ, Han JH, Lee JH, Lee WS, Bae JM, et al. Autoimmune and autoinflammatory connective tissue disorders following COVID-19. JAMA Netw Open. 2023;6(10):e2336120. doi: 10.1001/jamanetworkopen.2023.36120Lim SH, Ju HJ, Han JH, Lee JH, Lee WS, Bae JM, et al. Autoimmune and autoinflammatory connective tissue disorders following COVID-19. JAMA Netw Open. 2023;6(10):e2336120. doi: 10.1001/jamanetworkopen.2023.36120Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. doi: 10.1016/j.clim.2020.108480Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. doi: 10.1016/j.clim.2020.108480Насонов ЕЛ, Белов БС, Лила АМ, Аронова ЕС, Гриднева ГИ, Кудрявцева АВ, и др. Течение и исходы COVID-19 у пациентов с иммуновоспалительными ревматическими заболеваниями: предварительные данные регистра НИИР/АРР-COVID-19 и обзор литературы. Научно-практическая ревматология. 2021;59(6):666-675. doi: 10.47360/1995-4484-2021-666-675Nasonov EL, Belov BS, Lila AM, Aronova ES, Gridneva GI, Kudryavtseva AV, et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(6):666-675 (In Russ.) doi: 10.47360/1995-4484-2021-666-675Gauckler P, Kesenheimer JS, Geetha D, Odler B, Eller K, Laboux T, et al. COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases. Front Immunol. 2023;14:1228457. doi: 10.3389/fimmu.2023.1228457Gauckler P, Kesenheimer JS, Geetha D, Odler B, Eller K, Laboux T, et al. COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases. Front Immunol. 2023;14:1228457. doi: 10.3389/fimmu.2023.1228457Conway R, Grimshaw AA, Konig MF, Putman M, Duarte-García A, Tseng LY, et al.; COVID-19 Global Rheumatology Alliance. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: A systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74(5):766-775. doi: 10.1002/art.42030Conway R, Grimshaw AA, Konig MF, Putman M, DuarteGarcía A, Tseng LY, et al.; COVID-19 Global Rheumatology Alliance. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: A systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74(5):766-775. doi: 10.1002/art.42030Мазуров ВИ, Беляева ИБ, Саранцева ЛЕ, Чудинов АЛ, Башкинов РА, Трофимов ЕА, и др. Особенности клинического течения ревматических заболеваний у пациентов, перенесших новую коронавирусную инфекцию. Терапия. 2021;7(10):42-54. doi: 10.18565/therapy.2021.10.42-54Mazurov VI, Belyaeva IB, Sarantseva LE, Chudinov AL, Bashkinov RA, Trofimov ЕА, et al. Features of the clinical course of rheumatic diseases in patients who have had a new coronavirus infection. 2021;7(10):42-54 (In Russ.) doi: 10.18565/therapy.2021.10.42-54Figueroa-Parra G, Gilbert EL, Valenzuela-Almada MO, Vallejo S, Neville MR, Patel NJ, et al. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: A retrospective, comparative, multicentre cohort study. Lancet Rheumatol. 2022;4(11):e765-e774. doi: 10.1016/S2665-9913(22)00227-2Figueroa-Parra G, Gilbert EL, Valenzuela-Almada MO, Vallejo S, Neville MR, Patel NJ, et al. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: A retrospective, comparative, multicentre cohort study. Lancet Rheumatol. 2022;4(11):e765-e774. doi: 10.1016/S2665-9913(22)00227-2Zaccardelli A, Wallace ZS, Sparks JA. Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: Lessons learned and emerging directions 3 years into the pandemic. Curr Opin Rheumatol. 2023;35(3):175-184. doi: 10.1097/BOR.0000000000000930Zaccardelli A, Wallace ZS, Sparks JA. Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: Lessons learned and emerging directions 3 years into the pandemic. Curr Opin Rheumatol. 2023;35(3):175-184. doi: 10.1097/BOR.0000000000000930Di Iorio M, Cook CE, Vanni KMM, Patel NJ, D’Silva KM, Fu X, et al. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. Semin Arthritis Rheum. 2022;55:152025. doi: 10.1016/j.semarthrit.2022.152025Di Iorio M, Cook CE, Vanni KMM, Patel NJ, D’Silva KM, Fu X, et al. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. Semin Arthritis Rheum. 2022;55:152025. doi: 10.1016/j.semarthrit.2022.152025DiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, et al. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2022;8(2):e002587. doi: 10.1136/rmdopen-2022-002587DiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, et al. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2022;8(2):e002587. doi: 10.1136/rmdopen-2022-002587Куликов АН, Муравьева НВ, Белов БС. Частота и течение COVID-19 у больных ревматическими заболеваниями (по данным ФГБНУ НИИР им. В.А. Насоновой). Научно-практическая ревматология. 2023;61(5):537-544. doi: 10.47360/1995-4484-2023-537-544Kulikov AN, Muravyeva NV, Belov BS. Frequency and course of COVID-19 in patients with rheumatic diseases (according to the data of V.A. Nasonova Research Institute of Rheumatology). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(5):537-544 (In Russ.) doi: 10.47360/1995-4484-2023-537-544D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020;79(9):1156-1162. doi: 10.1136/annrheumdis-2020-217888D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020;79(9):1156-1162. doi: 10.1136/annrheumdis-2020-217888Patel NJ, D’Silva KM, Li MD, Hsu TYT, DiIorio M, Fu X, et al. Assessing the severity of COVID-19 lung injury in rheumatic diseases versus the general population using deep learning-derived chest radiograph scores. Arthritis Care Res (Hoboken). 2023;75(3):657-666. doi: 10.1002/acr.24883Patel NJ, D’Silva KM, Li MD, Hsu TYT, DiIorio M, Fu X, et al. Assessing the severity of COVID-19 lung injury in rheumatic diseases versus the general population using deep learning-derived chest radiograph scores. Arthritis Care Res (Hoboken). 2023;75(3):657-666. doi: 10.1002/acr.24883D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi: 10.1002/art.41619D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi: 10.1002/art.41619Jorge A, D’Silva KM, Cohen A, Wallace ZS, McCormick N, Zhang Y, et al. Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: A cohort study. Lancet Rheumatol. 2021;3(2):e131-e137. doi: 10.1016/S2665-9913(20)30422-7Jorge A, D’Silva KM, Cohen A, Wallace ZS, McCormick N, Zhang Y, et al. Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: A cohort study. Lancet Rheumatol. 2021;3(2):e131-e137. doi: 10.1016/S2665-9913(20)30422-7Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A populationbased cohort study. PLoS One. 2021;16(10):e0258154. doi: 10.1371/journal.pone.0258154Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A populationbased cohort study. PLoS One. 2021;16(10):e0258154. doi: 10.1371/journal.pone.0258154England BR, Roul P, Yang Y, Kalil AC, Michaud K, Thiele GM, et al. Risk of COVID-19 in rheumatoid arthritis: A National Veterans Affairs matched cohort study in at-risk individuals. Arthritis Rheumatol. 2021;73(12):2179-2188. doi: 10.1002/art.41800England BR, Roul P, Yang Y, Kalil AC, Michaud K, Thiele GM, et al. Risk of COVID-19 in rheumatoid arthritis: A National Veterans Affairs matched cohort study in at-risk individuals. Arthritis Rheumatol. 2021;73(12):2179-2188. doi: 10.1002/art.41800Curtis JR, Zhou X, Rubin DT, Reinisch W, Yazdany J, Robinson PC, et al. Characteristics, comorbidities, and outcomes of SARS-CoV-2 infection in patients with autoimmune conditions treated with systemic therapies: A population-based study. J Rheumatol. 2022;49(3):320-329. doi: 10.3899/jrheum.210888Curtis JR, Zhou X, Rubin DT, Reinisch W, Yazdany J, Robinson PC, et al. Characteristics, comorbidities, and outcomes of SARS-CoV-2 infection in patients with autoimmune conditions treated with systemic therapies: A population-based study. J Rheumatol. 2022;49(3):320-329. doi: 10.3899/jrheum.210888Raiker R, DeYoung C, Pakhchanian H, Ahmed S, Kavadichanda C, Gupta L, et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum. 2021;51(5):1057-1066. doi: 10.1016/j.semarthrit.2021.08.010Raiker R, DeYoung C, Pakhchanian H, Ahmed S, Kavadichanda C, Gupta L, et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum. 2021;51(5):1057-1066. doi: 10.1016/j.semarthrit.2021.08.010Li H, Wallace ZS, Sparks JA, Lu N, Wei J, Xie D, et al. Risk of COVID-19 among unvaccinated and vaccinated patients with rheumatoid arthritis: A general population study. Arthritis Care Res (Hoboken). 2023;75(5):956-966. doi: 10.1002/acr.25028Li H, Wallace ZS, Sparks JA, Lu N, Wei J, Xie D, et al. Risk of COVID-19 among unvaccinated and vaccinated patients with rheumatoid arthritis: A general population study. Arthritis Care Res (Hoboken). 2023;75(5):956-966. doi: 10.1002/acr.25028Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi: 10.1038/s41586-020-2521-4Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi: 10.1038/s41586-020-2521-4Williamson J, Black L, Black A, Koduri G, Kelly C. There are similarities between rheumatic disease with lung involvement and COVID-19 pneumonia. Ir J Med Sci. 2022;191(1):1-5. doi: 10.1007/s11845-021-02545-yWilliamson J, Black L, Black A, Koduri G, Kelly C. There are similarities between rheumatic disease with lung involvement and COVID-19 pneumonia. Ir J Med Sci. 2022;191(1):1-5. doi: 10.1007/s11845-021-02545-yFonseca M, Summer R, Roman J. Acute exacerbation of interstitial lung disease as a sequela of COVID-19 pneumonia. Am J Med Sci. 2021;361(1):126-129. doi: 10.1016/j.amjms.2020.08.017Fonseca M, Summer R, Roman J. Acute exacerbation of interstitial lung disease as a sequela of COVID-19 pneumonia. Am J Med Sci. 2021;361(1):126-129. doi: 10.1016/j.amjms.2020.08.017Torun S, Karaman I. Acute exacerbation of rheumatoid arthritis misdiagnosed as COVID-19: A case report. Front Med (Lausanne). 2022;9:844609. doi: 10.3389/fmed.2022.844609Torun S, Karaman I. Acute exacerbation of rheumatoid arthritis misdiagnosed as COVID-19: A case report. Front Med (Lausanne). 2022;9:844609. doi: 10.3389/fmed.2022.844609Lee AR, Woo JS, Lee SY, Lee YS, Jung J, Lee CR, et al. SARSCoV-2 spike protein promotes inflammatory cytokine activation and aggravates rheumatoid arthritis. Cell Commun Signal. 2023;21(1):44. doi: 10.1186/s12964-023-01044-0Lee AR, Woo JS, Lee SY, Lee YS, Jung J, Lee CR, et al. SARSCoV-2 spike protein promotes inflammatory cytokine activation and aggravates rheumatoid arthritis. Cell Commun Signal. 2023;21(1):44. doi: 10.1186/s12964-023-01044-0Isaacs JD, Burmester GR. Smart battles: Immunosuppression versus immunomodulation in the inflammatory RMDs. Ann Rheum Dis. 2020;79(8):991-993. doi: 10.1136/annrheumdis-2020-218019Isaacs JD, Burmester GR. Smart battles: Immunosuppression versus immunomodulation in the inflammatory RMDs. Ann Rheum Dis. 2020;79(8):991-993. doi: 10.1136/annrheumdis-2020-218019Venkat R, Wallace ZS, Sparks JA. Considerations for pharmacologic management of rheumatoid arthritis in the COVID-19 era: A narrative review. Curr Rheumatol Rep. 2023;25(11):236-245. doi: 10.1007/s11926-023-01111-yVenkat R, Wallace ZS, Sparks JA. Considerations for pharmacologic management of rheumatoid arthritis in the COVID-19 era: A narrative review. Curr Rheumatol Rep. 2023;25(11):236-245. doi: 10.1007/s11926-023-01111-yLee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi: 10.1038/s41573-020-00092-2Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi: 10.1038/s41573-020-00092-2Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. doi: 10.14412/1995-4484-2019-3-40Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.) doi: 10.14412/1995-4484-2019-3-40Насонов ЕЛ (ред.). Анти-В-клеточная терапия в ревматологии: Фокус на ритуксимаб. М.:ИМА-ПРЕСС;2012.Nasonov EL (ed.). Anti B cell therapy in rheumatology: A focus on rituximab. Moscow:IMA-PRESS;2012 (In Russ.)Насонов ЕЛ, Авдеева АС. Деплеция В-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (COVID-19). Научно-практическая ревматология. 2021;59(4):384-393. doi: 10.47360/1995-4484-2021-384-393Nasonov EL, Avdeeva AS. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):384-393 (In Russ.) doi: 10.47360/1995-4484-2021-384-393Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137-1146. doi: 10.1136/annrheumdis-2021-220418Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137-1146. doi: 10.1136/annrheumdis-2021-220418Singh N, Madhira V, Hu C, Olex AL, Bergquist T, Fitzgerald KC, et al. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C). Semin Arthritis Rheum. 2023;58:152149. doi: 10.1016/j.semarthrit.2022.152149Singh N, Madhira V, Hu C, Olex AL, Bergquist T, Fitzgerald KC, et al. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C). Semin Arthritis Rheum. 2023;58:152149. doi: 10.1016/j.semarthrit.2022.152149Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physicianreported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physicianreported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464. doi: 10.1136/rmdopen-2020-001464Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464. doi: 10.1136/rmdopen-2020-001464Tsai JJ, Liu LT, Chen CH, Chen LJ, Wang SI, Wei JC. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs. RMD Open. 2023;9(3):e003038. doi: 10.1136/rmdopen-2023-003038Tsai JJ, Liu LT, Chen CH, Chen LJ, Wang SI, Wei JC. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs. RMD Open. 2023;9(3):e003038. doi: 10.1136/rmdopen-2023-003038Rutter M, Lanyon PC, Grainge MJ, Hubbard R, Bythell M, Stilwell P, et al. COVID-19 infection, admission and death and the impact of corticosteroids among people with rare autoimmune rheumatic disease during the second wave of COVID-19 in England: Results from the RECORDER Project. Rheumatology (Oxford). 2023;62(12):3828-3837. doi: 10.1093/rheumatology/kead150Rutter M, Lanyon PC, Grainge MJ, Hubbard R, Bythell M, Stilwell P, et al. COVID-19 infection, admission and death and the impact of corticosteroids among people with rare autoimmune rheumatic disease during the second wave of COVID-19 in England: Results from the RECORDER Project. Rheumatology (Oxford). 2023;62(12):3828-3837. doi: 10.1093/rheumatology/kead150Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: A prospective cohort study. Ann Intern Med. 2021;174(11):1572-1585. doi: 10.7326/M21-1757Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: A prospective cohort study. Ann Intern Med. 2021;174(11):1572-1585. doi: 10.7326/M21-1757Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: A prospective, cohort study. Lancet Rheumatol. 2022;4(3):e177-e187. doi: 10.1016/S2665-9913(21)00394-5Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: A prospective, cohort study. Lancet Rheumatol. 2022;4(3):e177-e187. doi: 10.1016/S2665-9913(21)00394-5Johnson D, Jiang W. Infectious diseases, autoantibodies, and autoimmunity. J Autoimmun. 2023;137:102962. doi: 10.1016/j.jaut.2022.102962Johnson D, Jiang W. Infectious diseases, autoantibodies, and autoimmunity. J Autoimmun. 2023;137:102962. doi: 10.1016/j.jaut.2022.102962Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The role of viral infections in the onset of autoimmune diseases. Viruses. 2023;15(3):782. doi: 10.3390/v15030782Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The role of viral infections in the onset of autoimmune diseases. Viruses. 2023;15(3):782. doi: 10.3390/v15030782Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: Challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906-918. doi: 10.1182/blood-2018-11-882993Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: Challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906-918. doi: 10.1182/blood-2018-11-882993Wagner DD, Heger LA. Thromboinflammation: From atherosclerosis to COVID-19. Arterioscler Thromb Vasc Biol. 2022;42(9):1103-1112. doi: 10.1161/ATVBAHA.122.317162Wagner DD, Heger LA. Thromboinflammation: From atherosclerosis to COVID-19. Arterioscler Thromb Vasc Biol. 2022;42(9):1103-1112. doi: 10.1161/ATVBAHA.122.317162Jenks SA, Cashman KS, Woodruff MC, Lee FE, Sanz I. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288(1):136-148. doi: 10.1111/imr.12741Jenks SA, Cashman KS, Woodruff MC, Lee FE, Sanz I. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288(1):136-148. doi: 10.1111/imr.12741Chung MKY, Gong L, Kwong DL, Lee VH, Lee AW, Guan XY, et al. Functions of double-negative B cells in autoimmune diseases, infections, and cancers. EMBO Mol Med. 2023;15(9):e17341. doi: 10.15252/emmm.202217341Chung MKY, Gong L, Kwong DL, Lee VH, Lee AW, Guan XY, et al. Functions of double-negative B cells in autoimmune diseases, infections, and cancers. EMBO Mol Med. 2023;15(9):e17341. doi: 10.15252/emmm.202217341Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21(12):1506-1516. doi: 10.1038/s41590-020-00814-zWoodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21(12):1506-1516. doi: 10.1038/s41590-020-00814-zBortolotti D, Gentili V, Rizzo S, Schiuma G, Beltrami S, Strazzabosco G, et al. TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection. Microorganisms. 2021;9(9):1820. doi: 10.3390/microorganisms9091820Bortolotti D, Gentili V, Rizzo S, Schiuma G, Beltrami S, Strazzabosco G, et al. TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection. Microorganisms. 2021;9(9):1820. doi: 10.3390/microorganisms9091820Fillatreau S, Manfroi B, Dörner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(2):98-108. doi: 10.1038/s41584-020-00544-4Fillatreau S, Manfroi B, Dörner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(2):98-108. doi: 10.1038/s41584-020-00544-4Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies targeting intracellular and extracellular proteins in autoimmunity. Front Immunol. 2021;12:548469. doi: 10.3389/fimmu.2021.548469Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies targeting intracellular and extracellular proteins in autoimmunity. Front Immunol. 2021;12:548469. doi: 10.3389/fimmu.2021.548469Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017;8:603. doi: 10.3389/fimmu.2017.00603Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017;8:603. doi: 10.3389/fimmu.2017.00603Puel A, Bastard P, Bustamante J, Casanova JL. Human autoantibodies underlying infectious diseases. J Exp Med. 2022;219(4):e20211387. doi: 10.1084/jem.20211387Puel A, Bastard P, Bustamante J, Casanova JL. Human autoantibodies underlying infectious diseases. J Exp Med. 2022;219(4):e20211387. doi: 10.1084/jem.20211387Moritz CP, Paul S, Stoevesandt O, Tholance Y, Camdessanché JP, Antoine JC. Autoantigenomics: Holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases. Autoimmun Rev. 2020;19(2):102450. doi: 10.1016/j.autrev.2019.102450Moritz CP, Paul S, Stoevesandt O, Tholance Y, Camdessanché JP, Antoine JC. Autoantigenomics: Holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases. Autoimmun Rev. 2020;19(2):102450. doi: 10.1016/j.autrev.2019.102450Damoiseaux J, Dotan A, Fritzler MJ, Bogdanos DP, Meroni PL, Roggenbuck D, et al. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev. 2022;21(3):103012. doi: 10.1016/j.autrev.2021.103012Damoiseaux J, Dotan A, Fritzler MJ, Bogdanos DP, Meroni PL, Roggenbuck D, et al. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev. 2022;21(3):103012. doi: 10.1016/j.autrev.2021.103012Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021;59(1):5-30. doi: 10.47360/1995-4484-2021-5-30Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):5-30 (In Russ.) doi: 10.47360/1995-4484-2021-5-30Dobrowolska K, Zarębska-Michaluk D, Poniedziałek B, Jaroszewicz J, Flisiak R, Rzymski P. Overview of autoantibodies in COVID-19 convalescents. J Med Virol. 2023;95(6):e28864. doi: 10.1002/jmv.28864Dobrowolska K, Zarębska-Michaluk D, Poniedziałek B, Jaroszewicz J, Flisiak R, Rzymski P. Overview of autoantibodies in COVID-19 convalescents. J Med Virol. 2023;95(6):e28864. doi: 10.1002/jmv.28864Rojas M, Rodríguez Y, Acosta-Ampudia Y, Monsalve DM, Zhu C, Li QZ, et al. Autoimmunity is a hallmark of post-COVID syndrome. J Transl Med. 2022;20(1):129. doi: 10.1186/s12967-022-03328-4Rojas M, Rodríguez Y, Acosta-Ampudia Y, Monsalve DM, Zhu C, Li QZ, et al. Autoimmunity is a hallmark of post-COVID syndrome. J Transl Med. 2022;20(1):129. doi: 10.1186/s12967-022-03328-4Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021 ;12(1):5417. doi: 10.1038/s41467-021-25509-3Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021 ;12(1):5417. doi: 10.1038/s41467-021-25509-3Moody R, Sonda S, Johnston FH, Smith KJ, Stephens N, McPherson M, et al. Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes. Front Immunol. 2022;13:945021. doi: 10.3389/fimmu.2022.945021Moody R, Sonda S, Johnston FH, Smith KJ, Stephens N, McPherson M, et al. Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes. Front Immunol. 2022;13:945021. doi: 10.3389/fimmu.2022.945021Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: Implications for autoimmune diseases. Front Immunol. 2021;11:617089. doi: 10.3389/fimmu.2020.617089Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: Implications for autoimmune diseases. Front Immunol. 2021;11:617089. doi: 10.3389/fimmu.2020.617089McGill JR, Lagassé HAD, Hernandez N, Hopkins L, Jankowski W, McCormick Q, et al. A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection. Sci Rep. 2022;12(1):11388. doi: 10.1038/s41598-022-15225-3McGill JR, Lagassé HAD, Hernandez N, Hopkins L, Jankowski W, McCormick Q, et al. A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection. Sci Rep. 2022;12(1):11388. doi: 10.1038/s41598-022-15225-3Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi: 10.1126/science.abd4585Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi: 10.1126/science.abd4585Bastard P, Zhang Q, Zhang SY, Jouanguy E, Casanova JL. Type I interferons and SARS-CoV-2: From cells to organisms. Curr Opin Immunol. 2022;74:172-182. doi: 10.1016/j.coi.2022.01.003Bastard P, Zhang Q, Zhang SY, Jouanguy E, Casanova JL. Type I interferons and SARS-CoV-2: From cells to organisms. Curr Opin Immunol. 2022;74:172-182. doi: 10.1016/j.coi.2022.01.003Su HC, Jing H, Zhang Y, Casanova JL. Interfering with interferons: A critical mechanism for critical COVID-19 pneumonia. Annu Rev Immunol. 2023;41:561-585. doi: 10.1146/annurevimmunol-101921-050835Su HC, Jing H, Zhang Y, Casanova JL. Interfering with interferons: A critical mechanism for critical COVID-19 pneumonia. Annu Rev Immunol. 2023;41:561-585. doi: 10.1146/annurevimmunol-101921-050835Zhang Q, Bastard P; COVID Human Genetic Effort; Cobat A, Casanova JL. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603(7902):587-598. doi: 10.1038/s41586-022-04447-0Zhang Q, Bastard P; COVID Human Genetic Effort; Cobat A, Casanova JL. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603(7902):587-598. doi: 10.1038/s41586-022-04447-0Bastard P, Vazquez SE, Liu J, Laurie MT, Wang CY, Gervais A, et al. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunol. 2023;8(90):eabp8966. doi: 10.1126/sciimmunol.abp8966Bastard P, Vazquez SE, Liu J, Laurie MT, Wang CY, Gervais A, et al. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunol. 2023;8(90):eabp8966. doi: 10.1126/sciimmunol.abp8966Gupta S, Nakabo S, Chu J, Hasni S, Kaplan MJ. Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus. medRxiv. 2020:2020.10.29.20222000. doi: 10.1101/2020.10.29.20222000Gupta S, Nakabo S, Chu J, Hasni S, Kaplan MJ. Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus. medRxiv. 2020:2020.10.29.20222000. doi: 10.1101/2020.10.29.20222000Beydon M, Nicaise-Roland P, Mageau A, Farkh C, Daugas E, Descamps V, et al. Autoantibodies against IFNα in patients with systemic lupus erythematosus and susceptibility for infection: A retrospective case-control study. Sci Rep. 2022;12(1):11244. doi: 10.1038/s41598-022-15508-9Beydon M, Nicaise-Roland P, Mageau A, Farkh C, Daugas E, Descamps V, et al. Autoantibodies against IFNα in patients with systemic lupus erythematosus and susceptibility for infection: A retrospective case-control study. Sci Rep. 2022;12(1):11244. doi: 10.1038/s41598-022-15508-9Peluso MJ, Mitchell A, Wang CY, Takahashi S, Hoh R, Tai V, et al. Low prevalence of interferon α autoantibodies in people experiencing symptoms of post-coronavirus disease 2019 (COVID-19) conditions, or long COVID. J Infect Dis. 2023;227(2):246-250. doi: 10.1093/infdis/jiac372Peluso MJ, Mitchell A, Wang CY, Takahashi S, Hoh R, Tai V, et al. Low prevalence of interferon α autoantibodies in people experiencing symptoms of post-coronavirus disease 2019 (COVID-19) conditions, or long COVID. J Infect Dis. 2023;227(2):246-250. doi: 10.1093/infdis/jiac372Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283-288. doi: 10.1038/s41586-021-03631-yWang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283-288. doi: 10.1038/s41586-021-03631-yWang EY, Dai Y, Rosen CE, Schmitt MM, Dong MX, Ferré EMN, et al. High-throughput identification of autoantibodies that target the human exoproteome. Cell Rep Methods. 2022;2(2):100172. doi: 10.1016/j.crmeth.2022.100172Wang EY, Dai Y, Rosen CE, Schmitt MM, Dong MX, Ferré EMN, et al. High-throughput identification of autoantibodies that target the human exoproteome. Cell Rep Methods. 2022;2(2):100172. doi: 10.1016/j.crmeth.2022.100172Lichtenstein B, Zheng Y, Gjertson D, Ferbas KG, Rimoin AW, Yang OO, et al. Vascular and non-HLA autoantibody profiles in hospitalized patients with COVID-19. Front Immunol. 2023;14:1197326. doi: 10.3389/fimmu.2023.1197326Lichtenstein B, Zheng Y, Gjertson D, Ferbas KG, Rimoin AW, Yang OO, et al. Vascular and non-HLA autoantibody profiles in hospitalized patients with COVID-19. Front Immunol. 2023;14:1197326. doi: 10.3389/fimmu.2023.1197326Насонов ЕЛ (ред.). Антифосфолипидный синдром. М.:Литтерра;2004.Nasonov EL (ed.). Antiphospholipid syndrom. Moscow:Litterra;2004 (In Russ.)Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021. doi: 10.1056/NEJMra1705454Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021. doi: 10.1056/NEJMra1705454Pignatelli P, Ettorre E, Menichelli D, Pani A, Violi F, Pastori D. Seronegative antiphospholipid syndrome: Refining the value of “non-criteria” antibodies for diagnosis and clinical management. Haematologica. 2020;105(3):562-572. doi: 10.3324/haematol.2019.221945Pignatelli P, Ettorre E, Menichelli D, Pani A, Violi F, Pastori D. Seronegative antiphospholipid syndrome: Refining the value of “non-criteria” antibodies for diagnosis and clinical management. Haematologica. 2020;105(3):562-572. doi: 10.3324/haematol.2019.221945Liu X, Zhu L, Liu H, Cai Q, Yun Z, Sun F, et al. Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added. Front Immunol. 2022;13:972012. doi: 10.3389/fimmu.2022.972012Liu X, Zhu L, Liu H, Cai Q, Yun Z, Sun F, et al. Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added. Front Immunol. 2022;13:972012. doi: 10.3389/fimmu.2022.972012Shi H, Zuo Y, Navaz S, Harbaugh A, Hoy CK, Gandhi AA, et al. Endothelial cell-activating antibodies in COVID-19. Arthritis Rheumatol. 2022;74(7):1132-1138. doi: 10.1002/art.42094Shi H, Zuo Y, Navaz S, Harbaugh A, Hoy CK, Gandhi AA, et al. Endothelial cell-activating antibodies in COVID-19. Arthritis Rheumatol. 2022;74(7):1132-1138. doi: 10.1002/art.42094Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876. doi: 10.1126/scitranslmed.abd3876Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876. doi: 10.1126/scitranslmed.abd3876Favaloro EJ, Pasalic L, Lippi G. Antibodies against platelet factor 4 and their associated pathologies: From HIT/HITT to spontaneous HIT-like syndrome, to COVID-19, to VITT/ TTS. Antibodies (Basel). 2022;11(1):7. doi: 10.3390/antib11010007.Favaloro EJ, Pasalic L, Lippi G. Antibodies against platelet factor 4 and their associated pathologies: From HIT/HITT to spontaneous HIT-like syndrome, to COVID-19, to VITT/ TTS. Antibodies (Basel). 2022;11(1):7. doi: 10.3390/antib11010007.Hollerbach A, Müller-Calleja N, Pedrosa D, Canisius A, Sprinzl MF, Falter T, et al. Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J Thromb Haemost. 2021;19(9):2335-2347. doi: 10.1111/jth.15455Hollerbach A, Müller-Calleja N, Pedrosa D, Canisius A, Sprinzl MF, Falter T, et al. Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J Thromb Haemost. 2021;19(9):2335-2347. doi: 10.1111/jth.15455Zuniga M, Gomes C, Carsons SE, Bender MT, Cotzia P, Miao QR, et al. Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients. Eur Respir J. 2021;58(4):2100918. doi: 10.1183/13993003.00918-2021Zuniga M, Gomes C, Carsons SE, Bender MT, Cotzia P, Miao QR, et al. Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients. Eur Respir J. 2021;58(4):2100918. doi: 10.1183/13993003.00918-2021Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: A meta-analysis and systematic review. RMD Open. 2021;7(2):e001580. doi: 10.1136/rmdopen-2021-001580Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: A meta-analysis and systematic review. RMD Open. 2021;7(2):e001580. doi: 10.1136/rmdopen-2021-001580Butt A, Erkan D, Lee AI. COVID-19 and antiphospholipid antibodies. Best Pract Res Clin Haematol. 2022;35(3):101402. doi: 10.1016/j.beha.2022.101402Butt A, Erkan D, Lee AI. COVID-19 and antiphospholipid antibodies. Best Pract Res Clin Haematol. 2022;35(3):101402. doi: 10.1016/j.beha.2022.101402Meroni PL, Borghi MO. Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: One swallow does not make a summer. Ann Rheum Dis. 2021;80(9):1105-1107. doi: 10.1136/annrheumdis-2021-220520Meroni PL, Borghi MO. Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: One swallow does not make a summer. Ann Rheum Dis. 2021;80(9):1105-1107. doi: 10.1136/annrheumdis-2021-220520Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: Time for a reality check? Semin Thromb Hemost. 2022;48(1):72-92. doi: 10.1055/s-0041-1728832Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: Time for a reality check? Semin Thromb Hemost. 2022;48(1):72-92. doi: 10.1055/s-0041-1728832Serrano M, Espinosa G, Serrano A, Cervera R. COVID-19 and the antiphospholipid syndrome. Autoimmun Rev. 2022;21(12):103206. doi: 10.1016/j.autrev.2022.103206Serrano M, Espinosa G, Serrano A, Cervera R. COVID-19 and the antiphospholipid syndrome. Autoimmun Rev. 2022;21(12):103206. doi: 10.1016/j.autrev.2022.103206Mendel A, Fritzler MJ, St-Pierre Y, Rauch J, Bernatsky S, Vinet É. Outcomes associated with antiphospholipid antibodies in COVID-19: A prospective cohort study. Res Pract Thromb Haemost. 2023;7(1):100041. doi: 10.1016/j.rpth.2023.100041Mendel A, Fritzler MJ, St-Pierre Y, Rauch J, Bernatsky S, Vinet É. Outcomes associated with antiphospholipid antibodies in COVID-19: A prospective cohort study. Res Pract Thromb Haemost. 2023;7(1):100041. doi: 10.1016/j.rpth.2023.100041Weiss R, Bushi D, Mindel E, Bitton A, Diesendruck Y, Gera O, et al. Autoantibodies to annexin A2 and cerebral thrombosis: Insights from a mouse model. Lupus. 2021;30(5):775-784. doi: 10.1177/0961203321992117Weiss R, Bushi D, Mindel E, Bitton A, Diesendruck Y, Gera O, et al. Autoantibodies to annexin A2 and cerebral thrombosis: Insights from a mouse model. Lupus. 2021;30(5):775-784. doi: 10.1177/0961203321992117Benjamin LA, Paterson RW, Moll R, Pericleous C, Brown R, Mehta PR, et al.; UCLH Queen Square COVID-19 Biomarker Study group. Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. EClinicalMedicine. 2021;39:101070. doi: 10.1016/j.eclinm.2021.101070Benjamin LA, Paterson RW, Moll R, Pericleous C, Brown R, Mehta PR, et al.; UCLH Queen Square COVID-19 Biomarker Study group. Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. EClinicalMedicine. 2021;39:101070. doi: 10.1016/j.eclinm.2021.101070Alijotas-Reig J, Anunciación-Llunell A, Morales-Pérez S, Trapé J, Esteve-Valverde E, Miro-Mur F. Thrombosis and hyperinflammation in COVID-19 acute phase are related to anti-phosphatidylserine and anti-phosphatidylinositol antibody positivity. Biomedicines. 2023;11(8):2301. doi: 10.3390/biomedicines11082301Alijotas-Reig J, Anunciación-Llunell A, Morales-Pérez S, Trapé J, Esteve-Valverde E, Miro-Mur F. Thrombosis and hyperinflammation in COVID-19 acute phase are related to anti-phosphatidylserine and anti-phosphatidylinositol antibody positivity. Biomedicines. 2023;11(8):2301. doi: 10.3390/biomedicines11082301Doevelaar AAN, Bachmann M, Hölzer B, Seibert FS, Rohn BJ, Witzke O, et al. Generation of inhibitory autoantibodies to ADAMTS13 in coronavirus disease 2019. medRxiv. 2021.03.18.21253869. doi: 10.1101/2021.03.18.21253869Doevelaar AAN, Bachmann M, Hölzer B, Seibert FS, Rohn BJ, Witzke O, et al. Generation of inhibitory autoantibodies to ADAMTS13 in coronavirus disease 2019. medRxiv. 2021.03.18.21253869. doi: 10.1101/2021.03.18.21253869Yun J, Gu J, Kim HK. Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies enhances both thrombosis and positivity of antiADAMTS13 antibody. J Thromb Thrombolysis. 2021;52(4):1133-1136. doi: 10.1007/s11239-021-02406-6Yun J, Gu J, Kim HK. Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies enhances both thrombosis and positivity of antiADAMTS13 antibody. J Thromb Thrombolysis. 2021;52(4):1133-1136. doi: 10.1007/s11239-021-02406-6Brodard J, Kremer Hovinga JA, Fontana P, Studt JD, Gruel Y, Greinacher A. COVID-19 patients often show high-titer nonplatelet-activating anti-PF4/heparin IgG antibodies. J Thromb Haemost. 2021;19(5):1294-1298. doi: 10.1111/jth.15262Brodard J, Kremer Hovinga JA, Fontana P, Studt JD, Gruel Y, Greinacher A. COVID-19 patients often show high-titer nonplatelet-activating anti-PF4/heparin IgG antibodies. J Thromb Haemost. 2021;19(5):1294-1298. doi: 10.1111/jth.15262Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101. doi: 10.1056/NEJMoa2104840Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101. doi: 10.1056/NEJMoa2104840Woodruff MC, Ramonell RP, Haddad NS, Anam FA, Rudolph ME, Walker TA, et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature. 2022;611(7934):139-147. doi: 10.1038/s41586-022-05273-0Woodruff MC, Ramonell RP, Haddad NS, Anam FA, Rudolph ME, Walker TA, et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature. 2022;611(7934):139-147. doi: 10.1038/s41586-022-05273-0Gomes C, Zuniga M, Crotty KA, Qian K, Lin LH, Argyropoulos KV, et al. Autoimmune anti-DNA antibodies predict disease severity in COVID-19 patients. medRxiv. 2021.01.04.20249054. doi: 10.1101/2021.01.04.20249054Gomes C, Zuniga M, Crotty KA, Qian K, Lin LH, Argyropoulos KV, et al. Autoimmune anti-DNA antibodies predict disease severity in COVID-19 patients. medRxiv. 2021.01.04.20249054. doi: 10.1101/2021.01.04.20249054Cheng AP, Cheng MP, Gu W, Sesing Lenz J, Hsu E, Schurr E, et al. Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med. 2021;2(4):411-422.e5. doi: 10.1016/j.medj.2021.01.001Cheng AP, Cheng MP, Gu W, Sesing Lenz J, Hsu E, Schurr E, et al. Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med. 2021;2(4):411-422.e5. doi: 10.1016/j.medj.2021.01.001Etter MM, Martins TA, Kulsvehagen L, Pössnecker E, Duchemin W, Hogan S, et al. Severe neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: A prospective cross-sectional study. Nat Commun. 2022;13(1):6777. doi: 10.1038/s41467-022-34068-0Etter MM, Martins TA, Kulsvehagen L, Pössnecker E, Duchemin W, Hogan S, et al. Severe neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: A prospective cross-sectional study. Nat Commun. 2022;13(1):6777. doi: 10.1038/s41467-022-34068-0Basic-Jukic N, Pavlisa G, Sremec NT, Juric I, Ledenko R, Rogic D, et al. Autoantibodies in COVID-19, a possible role in the pathogenesis of the disease. Ther Apher Dial. 2023;27(5):882-889. doi: 10.1111/1744-9987.14004Basic-Jukic N, Pavlisa G, Sremec NT, Juric I, Ledenko R, Rogic D, et al. Autoantibodies in COVID-19, a possible role in the pathogenesis of the disease. Ther Apher Dial. 2023;27(5):882-889. doi: 10.1111/1744-9987.14004Park SH, Suh JW, Yang KS, Kim JY, Kim SB, Sohn JW, et al. Clinical significance of antinuclear antibody positivity in patients with severe coronavirus disease 2019. Korean J Intern Med. 2023;38(3):417-426. doi: 10.3904/kjim.2022.352Park SH, Suh JW, Yang KS, Kim JY, Kim SB, Sohn JW, et al. Clinical significance of antinuclear antibody positivity in patients with severe coronavirus disease 2019. Korean J Intern Med. 2023;38(3):417-426. doi: 10.3904/kjim.2022.352García-Abellán J, Fernández M, Padilla S, García JA, Agulló V, Lozano V, et al. Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol. 2022;13:920627. doi: 10.3389/fimmu.2022.920627García-Abellán J, Fernández M, Padilla S, García JA, Agulló V, Lozano V, et al. Immunologic phenotype of patients with longCOVID syndrome of 1-year duration. Front Immunol. 2022;13:920627. doi: 10.3389/fimmu.2022.920627Richter AG, Shields AM, Karim A, Birch D, Faustini SE, Steadman L, et al. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin Exp Immunol. 2021;205(2):99-105. doi: 10.1111/cei.13623Richter AG, Shields AM, Karim A, Birch D, Faustini SE, Steadman L, et al. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin Exp Immunol. 2021;205(2):99-105. doi: 10.1111/cei.13623Sacchi MC, Pelazza C, Bertolotti M, Agatea L, De Gaspari P, Tamiazzo S, et al. The onset of de novo autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: A single centre prospective follow-up study. Autoimmunity. 2023;56(1):2229072. doi: 10.1080/08916934.2023.2229072Sacchi MC, Pelazza C, Bertolotti M, Agatea L, De Gaspari P, Tamiazzo S, et al. The onset of de novo autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: A single centre prospective follow-up study. Autoimmunity. 2023;56(1):2229072. doi: 10.1080/08916934.2023.2229072Zhang W, Tao Y, Zhu Y, Zheng Q, Hu F, Zhu W, et al. Effect of serum autoantibodies on the COVID-19 patient’s prognosis. Front Microbiol. 2023;14:1259960. doi: 10.3389/fmicb.2023.1259960Zhang W, Tao Y, Zhu Y, Zheng Q, Hu F, Zhu W, et al. Effect of serum autoantibodies on the COVID-19 patient’s prognosis. Front Microbiol. 2023;14:1259960. doi: 10.3389/fmicb.2023.1259960Giannini M, Ohana M, Nespola B, Zanframundo G, Geny B, Meyer A. Similarities between COVID-19 and anti-MDA5 syndrome: What can we learn for better care? Eur Respir J. 2020;56(3):2001618. doi: 10.1183/13993003.01618-2020Giannini M, Ohana M, Nespola B, Zanframundo G, Geny B, Meyer A. Similarities between COVID-19 and anti-MDA5 syndrome: What can we learn for better care? Eur Respir J. 2020;56(3):2001618. doi: 10.1183/13993003.01618-2020Dias Junior AG, Sampaio NG, Rehwinkel J. A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol. 2019;27(1):75-85. doi: 10.1016/j.tim.2018.08.007Dias Junior AG, Sampaio NG, Rehwinkel J. A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol. 2019;27(1):75-85. doi: 10.1016/j.tim.2018.08.007Wang G, Wang Q, Wang Y, Liu C, Wang L, Chen H, et al. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: A retrospective cohort study. Front Immunol. 2021;12:791348. doi: 10.3389/fimmu.2021.791348Wang G, Wang Q, Wang Y, Liu C, Wang L, Chen H, et al. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: A retrospective cohort study. Front Immunol. 2021;12:791348. doi: 10.3389/fimmu.2021.791348Gonzalez D, Gupta L, Murthy V, Gonzalez EB, Williamson KA, Makol A, et al. Anti-MDA5 dermatomyositis after COVID-19 vaccination: A case-based review. Rheumatol Int. 2022;42(9):1629-1641. doi: 10.1007/s00296-022-05149-6Gonzalez D, Gupta L, Murthy V, Gonzalez EB, Williamson KA, Makol A, et al. Anti-MDA5 dermatomyositis after COVID-19 vaccination: A case-based review. Rheumatol Int. 2022;42(9):1629-1641. doi: 10.1007/s00296-022-05149-6Woodruff MC, Bonham KS, Anam FA, Walker TA, Faliti CE, Ishii Y, et al. Chronic inflammation, neutrophil activity, and autoreactivity splits long COVID. Nat Commun. 2023;14(1):4201. doi: 10.1038/s41467-023-40012-7Woodruff MC, Bonham KS, Anam FA, Walker TA, Faliti CE, Ishii Y, et al. Chronic inflammation, neutrophil activity, and autoreactivity splits long COVID. Nat Commun. 2023;14(1):4201. doi: 10.1038/s41467-023-40012-7Lingel H, Meltendorf S, Billing U, Thurm C, Vogel K, Majer C, et al. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J Autoimmun. 2021;122:102682. doi: 10.1016/j.jaut.2021.102682Lingel H, Meltendorf S, Billing U, Thurm C, Vogel K, Majer C, et al. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J Autoimmun. 2021;122:102682. doi: 10.1016/j.jaut.2021.102682Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.e20. doi: 10.1016/j.cell.2022.01.014Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.e20. doi: 10.1016/j.cell.2022.01.014Насонов ЕЛ, Попкова ТВ, Панафидина ТА. Проблемы ранней системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-128. doi: 10.47360/1995-4484-2021-119-128Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):119-128 (In Russ.) doi: 10.47360/1995-4484-2021-119-128Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur Respir J. 2023;61(1):2200970. doi: 10.1183/13993003.00970-2022Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur Respir J. 2023;61(1):2200970. doi: 10.1183/13993003.00970-2022Fonseca DLM, Filgueiras IS, Marques AHC, Vojdani E, Halpert G, Ostrinski Y, et al. Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: A systems biology approach. NPJ Aging. 2023;9(1):21. doi: 10.1038/s41514-023-00118-0Fonseca DLM, Filgueiras IS, Marques AHC, Vojdani E, Halpert G, Ostrinski Y, et al. Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: A systems biology approach. NPJ Aging. 2023;9(1):21. doi: 10.1038/s41514-023-00118-0Baiocchi GC, Vojdani A, Rosenberg AZ, Vojdani E, Halpert G, Ostrinski Y, et al. Autoantibodies linked to autoimmune diseases associate with COVID-19 outcomes. medRxiv. 2022.02.17.22271057. doi: 10.1101/2022.02.17.22271057Baiocchi GC, Vojdani A, Rosenberg AZ, Vojdani E, Halpert G, Ostrinski Y, et al. Autoantibodies linked to autoimmune diseases associate with COVID-19 outcomes. medRxiv. 2022.02.17.22271057. doi: 10.1101/2022.02.17.22271057COVID-19 Forecasting Team. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: A systematic analysis. Lancet. 2022;399(10334):1469-1488. doi: 10.1016/S0140-6736(21)02867-1COVID-19 Forecasting Team. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: A systematic analysis. Lancet. 2022;399(10334):1469-1488. doi: 10.1016/S0140-6736(21)02867-1Müller L, Di Benedetto S. From aging to long COVID: exploring the convergence of immunosenescence, inflammaging, and autoimmunity. Front Immunol. 2023;14:1298004. doi: 10.3389/fimmu.2023.1298004Müller L, Di Benedetto S. From aging to long COVID: exploring the convergence of immunosenescence, inflammaging, and autoimmunity. Front Immunol. 2023;14:1298004. doi: 10.3389/fimmu.2023.1298004Arvey A, Rowe M, Legutki JB, An G, Gollapudi A, Lei A, et al. Age-associated changes in the circulating human antibody repertoire are upregulated in autoimmunity. Immun Ageing. 2020;17:28. doi: 10.1186/s12979-020-00193-xArvey A, Rowe M, Legutki JB, An G, Gollapudi A, Lei A, et al. Age-associated changes in the circulating human antibody repertoire are upregulated in autoimmunity. Immun Ageing. 2020;17:28. doi: 10.1186/s12979-020-00193-xBaiocchi GC, Vojdani A, Rosenberg AZ, Vojdani E, Halpert G, Ostrinski Y, et al. Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity. J Med Virol. 2023;95(2):e28538. doi: 10.1002/jmv.28538Baiocchi GC, Vojdani A, Rosenberg AZ, Vojdani E, Halpert G, Ostrinski Y, et al. Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity. J Med Virol. 2023;95(2):e28538. doi: 10.1002/jmv.28538Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167-173. doi: 10.1016/j.cca.2020.04.027Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167-173. doi: 10.1016/j.cca.2020.04.027Rodriguez-Perez AI, Labandeira CM, Pedrosa MA, Valenzuela R, Suarez-Quintanilla JA, Cortes-Ayaso M, et al. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun. 2021;122:102683. doi: 10.1016/j.jaut.2021.102683Rodriguez-Perez AI, Labandeira CM, Pedrosa MA, Valenzuela R, Suarez-Quintanilla JA, Cortes-Ayaso M, et al. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun. 2021;122:102683. doi: 10.1016/j.jaut.2021.102683Casciola-Rosen L, Thiemann DR, Andrade F, Trejo-Zambrano MI, Leonard EK, Spangler JB, et al. IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight. 2022;7(9):e158362. doi: 10.1172/jci.insight.158362Casciola-Rosen L, Thiemann DR, Andrade F, Trejo-Zambrano MI, Leonard EK, Spangler JB, et al. IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight. 2022;7(9):e158362. doi: 10.1172/jci.insight.158362Miedema J, Schreurs M, van der Sar-van der Brugge S, Paats M, Baart S, Bakker M, et al. Antibodies against angiotensin II receptor type 1 and endothelin a receptor are associated with an unfavorable COVID19 disease course. Front Immunol. 2021;12:684142. doi: 10.3389/fimmu.2021.684142Miedema J, Schreurs M, van der Sar-van der Brugge S, Paats M, Baart S, Bakker M, et al. Antibodies against angiotensin II receptor type 1 and endothelin a receptor are associated with an unfavorable COVID19 disease course. Front Immunol. 2021;12:684142. doi: 10.3389/fimmu.2021.684142Briquez PS, Rouhani SJ, Yu J, Pyzer AR, Trujillo J, Dugan HL, et al. Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci Adv. 2022;8(40):eabn3777. doi: 10.1126/sciadv.abn3777Briquez PS, Rouhani SJ, Yu J, Pyzer AR, Trujillo J, Dugan HL, et al. Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci Adv. 2022;8(40):eabn3777. doi: 10.1126/sciadv.abn3777Cabral-Marques O, Halpert G, Schimke LF, Ostrinski Y, Vojdani A, Baiocchi GC, et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat Commun. 2022;13(1):1220. doi: 10.1038/s41467-022-28905-5Cabral-Marques O, Halpert G, Schimke LF, Ostrinski Y, Vojdani A, Baiocchi GC, et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat Commun. 2022;13(1):1220. doi: 10.1038/s41467-022-28905-5Sinnberg T, Lichtensteiger C, Ali OH, Pop OT, Jochum AK, Risch L, et al. Pulmonary surfactant proteins are inhibited by immunoglobulin a autoantibodies in severe COVID-19. Am J Respir Crit Care Med. 2023;207(1):38-49. doi: 10.1164/rccm.202201-0011OCSinnberg T, Lichtensteiger C, Ali OH, Pop OT, Jochum AK, Risch L, et al. Pulmonary surfactant proteins are inhibited by immunoglobulin a autoantibodies in severe COVID-19. Am J Respir Crit Care Med. 2023;207(1):38-49. doi: 10.1164/rccm.202201-0011OCMuri J, Cecchinato V, Cavalli A, Shanbhag AA, Matkovic M, Biggiogero M, et al. Autoantibodies against chemokines postSARS-CoV-2 infection correlate with disease course. Nat Immunol. 2023;24(4):604-611. doi: 10.1038/s41590-023-01445-wMuri J, Cecchinato V, Cavalli A, Shanbhag AA, Matkovic M, Biggiogero M, et al. Autoantibodies against chemokines postSARS-CoV-2 infection correlate with disease course. Nat Immunol. 2023;24(4):604-611. doi: 10.1038/s41590-023-01445-wThurner L, Fadle N, Bewarder M, Kos I, Regitz E, Cetin O, et al. Autoantibodies against progranulin and IL-1 receptor antagonist due to immunogenic posttranslational isoforms contribute to hyperinflammation in critically ill COVID-19. bioRxiv. 2021.04.23.441188. doi: 10.1101/2021.04.23.441188Thurner L, Fadle N, Bewarder M, Kos I, Regitz E, Cetin O, et al. Autoantibodies against progranulin and IL-1 receptor antagonist due to immunogenic posttranslational isoforms contribute to hyperinflammation in critically ill COVID-19. bioRxiv. 2021.04.23.441188. doi: 10.1101/2021.04.23.441188Pfeifer J, Thurner B, Kessel C, Fadle N, Kheiroddin P. Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: A multicentre, retrospective, cohort study. Lancet Rheumatol. 2022;4(5):e329-e337. doi: 10.1016/S2665-9913(22)00064-9Pfeifer J, Thurner B, Kessel C, Fadle N, Kheiroddin P. Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: A multicentre, retrospective, cohort study. Lancet Rheumatol. 2022;4(5):e329-e337. doi: 10.1016/S2665-9913(22)00064-9Potere N, Garrad E, Kanthi Y, Di Nisio M, Kaplanski G, Bonaventura A, et al. NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis. Cardiovasc Res. 2023;119(11):2046-2060. doi: 10.1093/cvr/cvad084Potere N, Garrad E, Kanthi Y, Di Nisio M, Kaplanski G, Bonaventura A, et al. NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis. Cardiovasc Res. 2023;119(11):2046-2060. doi: 10.1093/cvr/cvad084Jian J, Li G, Hettinghouse A, Liu C. Progranulin: A key player in autoimmune diseases. Cytokine. 2018;101:48-55. doi: 10.1016/j.cyto.2016.08.007Jian J, Li G, Hettinghouse A, Liu C. Progranulin: A key player in autoimmune diseases. Cytokine. 2018;101:48-55. doi: 10.1016/j.cyto.2016.08.007Klemm P, Assmann G, Preuss KD, Fadle N, Regitz E, Martin T, et al. Progranulin autoantibodies in systemic sclerosis and autoimmune connective tissue disorders: A preliminary study. Immun Inflamm Dis. 2019;7(4):271-275. doi: 10.1002/iid3.270Klemm P, Assmann G, Preuss KD, Fadle N, Regitz E, Martin T, et al. Progranulin autoantibodies in systemic sclerosis and autoimmune connective tissue disorders: A preliminary study. Immun Inflamm Dis. 2019;7(4):271-275. doi: 10.1002/iid3.270Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159-175. doi: 10.1038/nri3399Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159-175. doi: 10.1038/nri3399Li J, Zhang K, Zhang Y, Gu Z, Huang C. Neutrophils in COVID-19: Recent insights and advances. Virol J. 2023;20(1):169. doi: 10.1186/s12985-023-02116-wLi J, Zhang K, Zhang Y, Gu Z, Huang C. Neutrophils in COVID-19: Recent insights and advances. Virol J. 2023;20(1):169. doi: 10.1186/s12985-023-02116-wWigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2023;23(5):274-288. doi: 10.1038/s41577-022-00787-0Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2023;23(5):274-288. doi: 10.1038/s41577-022-00787-0Насонов ЕЛ, Авдеева АС, Решетняк ТМ, Алексанкин АП, Рубцов ЮП. Роль нетоза в патогенезе иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2023;61(5):513-530. doi: 10.47360/1995-4484-2023-513-530Nasonov EL, Avdeeva AS, Reshetnyak TM, Aleksankin AP, Rubtsov YuP. The role of NETosis in the pathogenesis of immunoinflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(5):513-530 (In Russ.) doi: 10.47360/1995-4484-2023-513-530Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999. doi: 10.1172/jci.insight.138999Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999. doi: 10.1172/jci.insight.138999Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, et al. Complement and tissue factorenriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020;130(11):6151-6157. doi: 10.1172/JCI141374Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, et al. Complement and tissue factorenriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020;130(11):6151-6157. doi: 10.1172/JCI141374Krinsky N, Sizikov S, Nissim S, Dror A, Sas A, Prinz H, et al. NETosis induction reflects COVID-19 severity and long COVID: Insights from a 2-center patient cohort study in Israel. J Thromb Haemost. 2023;21(9):2569-2584. doi: 10.1016/j.jtha.2023.02.033Krinsky N, Sizikov S, Nissim S, Dror A, Sas A, Prinz H, et al. NETosis induction reflects COVID-19 severity and long COVID: Insights from a 2-center patient cohort study in Israel. J Thromb Haemost. 2023;21(9):2569-2584. doi: 10.1016/j.jtha.2023.02.033Zuo Y, Yalavarthi S, Navaz SA, Hoy CK, Harbaugh A, Gockman K, et al. Autoantibodies stabilize neutrophil extracellular traps in COVID-19. JCI Insight. 2021;6(15):e150111. doi: 10.1172/jci.insight.150111Zuo Y, Yalavarthi S, Navaz SA, Hoy CK, Harbaugh A, Gockman K, et al. Autoantibodies stabilize neutrophil extracellular traps in COVID-19. JCI Insight. 2021;6(15):e150111. doi: 10.1172/jci.insight.150111Zuo Y, Navaz S, Tsodikov A, Kmetova K, Kluge L, Ambati A, et al.; Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. Anti-neutrophil extracellular trap antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for clinical trials and InternatiOnal Networking Clinical Database and Repository. Arthritis Rheumatol. 2023;75(8):1407-1414. doi: 10.1002/art.42489Zuo Y, Navaz S, Tsodikov A, Kmetova K, Kluge L, Ambati A, et al.; Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. Anti-neutrophil extracellular trap antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for clinical trials and InternatiOnal Networking Clinical Database and Repository. Arthritis Rheumatol. 2023;75(8):1407-1414. doi: 10.1002/art.42489Zuo Y, Yalavarthi S, Gockman K, Madison JA, Gudjonsson JE, Kahlenberg JM, et al. Anti-neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome. Arthritis Rheumatol. 2020;72(12):2130-2135. doi: 10.1002/art.41460Zuo Y, Yalavarthi S, Gockman K, Madison JA, Gudjonsson JE, Kahlenberg JM, et al. Anti-neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome. Arthritis Rheumatol. 2020;72(12):2130-2135. doi: 10.1002/art.41460Yalavarthi S, Gould TJ, Rao AN, Mazza LF, Morris AE, NúñezÁlvarez C, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: A newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 2015;67(11):2990-3003. doi: 10.1002/art.39247Yalavarthi S, Gould TJ, Rao AN, Mazza LF, Morris AE, NúñezÁlvarez C, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: A newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 2015;67(11):2990-3003. doi: 10.1002/art.39247Bertin D, Brodovitch A, Lopez A, Arcani R, Thomas GM, Beziane A, et al. Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19. Sci Rep. 2022;12(1):12523. doi: 10.1038/s41598-022-15969-yBertin D, Brodovitch A, Lopez A, Arcani R, Thomas GM, Beziane A, et al. Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19. Sci Rep. 2022;12(1):12523. doi: 10.1038/s41598-022-15969-yPisareva E, Badiou S, Mihalovičová L, Mirandola A, Pastor B, Kudriavtsev A, et al. Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute phase COVID-19 patients. J Med Virol. 2023;95(1):e28209. doi: 10.1002/jmv.28209Pisareva E, Badiou S, Mihalovičová L, Mirandola A, Pastor B, Kudriavtsev A, et al. Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute phase COVID-19 patients. J Med Virol. 2023;95(1):e28209. doi: 10.1002/jmv.28209Zha C, Zhang W, Gao F, Xu J, Jia R, Cai J, et al. Anti-β2 GPI/β2 GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4/MyD88/MAPKs axis activation. Neuropharmacology. 2018;138:140-150. doi: 10.1016/j.neuropharm.2018.06.001Zha C, Zhang W, Gao F, Xu J, Jia R, Cai J, et al. Anti-β2 GPI/β2 GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4/MyD88/MAPKs axis activation. Neuropharmacology. 2018;138:140-150. doi: 10.1016/j.neuropharm.2018.06.001Pisetsky DS. Antibodies to neutrophil extracellular traps: Novel markers for the antiphospholipid syndrome. Arthritis Rheumatol. 2023;75(8):1331-1333. doi: 10.1002/art.42548Pisetsky DS. Antibodies to neutrophil extracellular traps: Novel markers for the antiphospholipid syndrome. Arthritis Rheumatol. 2023;75(8):1331-1333. doi: 10.1002/art.42548Zelek WM, Harrison RA. Complement and COVID-19: Three years on, what we know, what we don’t know, and what we ought to know. Immunobiology. 2023;228(3):152393. doi: 10.1016/j.imbio.2023.152393Zelek WM, Harrison RA. Complement and COVID-19: Three years on, what we know, what we don’t know, and what we ought to know. Immunobiology. 2023;228(3):152393. doi: 10.1016/j.imbio.2023.152393Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538-547. doi: 10.1038/nrrheum.2017.125Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538-547. doi: 10.1038/nrrheum.2017.125Rawish E, Sauter M, Sauter R, Nording H, Langer HF. Complement, inflammation and thrombosis. Br J Pharmacol. 2021;178(14):2892-2904. doi: 10.1111/bph.15476Rawish E, Sauter M, Sauter R, Nording H, Langer HF. Complement, inflammation and thrombosis. Br J Pharmacol. 2021;178(14):2892-2904. doi: 10.1111/bph.15476Baines AC, Brodsky RA. Complementopathies. Blood Rev. 2017;31(4):213-223. doi: 10.1016/j.blre.2017.02.003Baines AC, Brodsky RA. Complementopathies. Blood Rev. 2017;31(4):213-223. doi: 10.1016/j.blre.2017.02.003Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U S A. 2020;117(40):25018-25025. doi: 10.1073/pnas.2010540117Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U S A. 2020;117(40):25018-25025. doi: 10.1073/pnas.2010540117Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun. 2021;116:102560. doi: 10.1016/j.jaut.2020.102560Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun. 2021;116:102560. doi: 10.1016/j.jaut.2020.102560Lo MW, Kemper C, Woodruff TM. COVID-19: Complement, coagulation, and collateral damage. J Immunol. 2020;205(6):1488-1495. doi: 10.4049/jimmunol.2000644Lo MW, Kemper C, Woodruff TM. COVID-19: Complement, coagulation, and collateral damage. J Immunol. 2020;205(6):1488-1495. doi: 10.4049/jimmunol.2000644Perez-Diez A, Liu X, Calderon S, Bennett A, Kisco A, et al. Prevalence and complement activation of anti-lymphocyte IgM antibodies in hospitalized COVID-19 patients. J Immunol. 2023;210(Suppl 1):75.26. doi: 10.4049/jimmunol.210.Suppl.7526Perez-Diez A, Liu X, Calderon S, Bennett A, Kisco A, et al. Prevalence and complement activation of anti-lymphocyte IgM antibodies in hospitalized COVID-19 patients. J Immunol. 2023;210(Suppl 1):75.26. doi: 10.4049/jimmunol.210.Suppl.7526Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135(4):239-251. doi: 10.1182/blood.2019003863Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135(4):239-251. doi: 10.1182/blood.2019003863Ghanbari EP, Jakobs K, Puccini M, Reinshagen L, Friebel J, Haghikia A, et al. The role of NETosis and complement activation in COVID-19-associated coagulopathies. Biomedicines. 2023;11(5):1371. doi: 10.3390/biomedicines11051371Ghanbari EP, Jakobs K, Puccini M, Reinshagen L, Friebel J, Haghikia A, et al. The role of NETosis and complement activation in COVID-19-associated coagulopathies. Biomedicines. 2023;11(5):1371. doi: 10.3390/biomedicines11051371Kolb P, Giese S, Voll RE, Hengel H, Falcone V. Immune complexes as culprits of immunopathology in severe COVID-19. Med Microbiol Immunol. 2023;212(2):185-191. doi: 10.1007/s00430-022-00743-8Kolb P, Giese S, Voll RE, Hengel H, Falcone V. Immune complexes as culprits of immunopathology in severe COVID-19. Med Microbiol Immunol. 2023;212(2):185-191. doi: 10.1007/s00430-022-00743-8Perdomo J, Leung HHL. Immune thrombosis: Exploring the significance of immune complexes and NETosis. Biology. 2023;12(10):1332. doi: 10.3390/biology12101332Perdomo J, Leung HHL. Immune thrombosis: Exploring the significance of immune complexes and NETosis. Biology. 2023;12(10):1332. doi: 10.3390/biology12101332Ankerhold J, Giese S, Kolb P, Maul-Pavicic A, Voll RE, Göppert N, et al. Circulating multimeric immune complexes contribute to immunopathology in COVID-19. Nat Commun. 2022;13(1):5654. doi: 10.1038/s41467-022-32867-zAnkerhold J, Giese S, Kolb P, Maul-Pavicic A, Voll RE, Göppert N, et al. Circulating multimeric immune complexes contribute to immunopathology in COVID-19. Nat Commun. 2022;13(1):5654. doi: 10.1038/s41467-022-32867-zPetrović T, Vijay A, Vučković F, Trbojević-Akmačić I, Ollivere BJ, Marjanović D, et al. IgG N-glycome changes during the course of severe COVID-19: An observational study. EBioMedicine. 2022;81:104101. doi: 10.1016/j.ebiom.2022.104101Petrović T, Vijay A, Vučković F, Trbojević-Akmačić I, Ollivere BJ, Marjanović D, et al. IgG N-glycome changes during the course of severe COVID-19: An observational study. EBioMedicine. 2022;81:104101. doi: 10.1016/j.ebiom.2022.104101Vučković F, Krištić J, Gudelj I, Teruel M, Keser T, Pezer M, et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. 2015;67(11):2978-2989. doi: 10.1002/art.39273Vučković F, Krištić J, Gudelj I, Teruel M, Keser T, Pezer M, et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. 2015;67(11):2978-2989. doi: 10.1002/art.39273Ramos-Martínez I, Ramos-Martínez E, Cerbón M, Pérez-Torres A, Pérez-Campos Mayoral L, Hernández-Huerta MT, et al. The role of B cell and T cell glycosylation in systemic lupus erythematosus. Int J Mol Sci. 2023;24(1):863. doi: 10.3390/ijms24010863Ramos-Martínez I, Ramos-Martínez E, Cerbón M, Pérez-Torres A, Pérez-Campos Mayoral L, Hernández-Huerta MT, et al. The role of B cell and T cell glycosylation in systemic lupus erythematosus. Int J Mol Sci. 2023;24(1):863. doi: 10.3390/ijms24010863Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187. doi: 10.1136/annrheumdis-2017-211555Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187. doi: 10.1136/annrheumdis-2017-211555Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. doi: 10.14412/1995-4484-2017-409-419Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(4):409-419 (In Russ.) doi: 10.14412/1995-4484-2017-409-419Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-412Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.) doi: 10.47360/1995-4484-2022-397-412Murakami N, Hayden R, Hills T, Al-Samkari H, Casey J, Del Sorbo L, et al. Therapeutic advances in COVID-19. Nat Rev Nephrol. 2023;19(1):38-52. doi: 10.1038/s41581-022-00642-4Murakami N, Hayden R, Hills T, Al-Samkari H, Casey J, Del Sorbo L, et al. Therapeutic advances in COVID-19. Nat Rev Nephrol. 2023;19(1):38-52. doi: 10.1038/s41581-022-00642-4Zhang W, Qin C, Fei Y, Shen M, Zhou Y, Zhang Y, et al. Antiinflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update. Clin Immunol. 2022;239:109022. doi: 10.1016/j.clim.2022.109022Zhang W, Qin C, Fei Y, Shen M, Zhou Y, Zhang Y, et al. Antiinflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update. Clin Immunol. 2022;239:109022. doi: 10.1016/j.clim.2022.109022Chee YJ, Fan BE, Young BE, Dalan R, Lye DC. Clinical trials on the pharmacological treatment of long COVID: A systematic review. J Med Virol. 2023;95(1):e28289. doi: 10.1002/jmv.28289Chee YJ, Fan BE, Young BE, Dalan R, Lye DC. Clinical trials on the pharmacological treatment of long COVID: A systematic review. J Med Virol. 2023;95(1):e28289. doi: 10.1002/jmv.28289Lopes LA, Agrawal DK. Thromboembolism in the complications of long COVID-19. Cardiol Cardiovasc Med. 2023;7(2):123-128. doi: 10.26502/fccm.92920317Lopes LA, Agrawal DK. Thromboembolism in the complications of long COVID-19. Cardiol Cardiovasc Med. 2023;7(2):123-128. doi: 10.26502/fccm.92920317Nicolai L, Kaiser R, Stark K. Thromboinflammation in long COVID – The elusive key to postinfection sequelae? J Thromb Haemost. 2023;21(8):2020-2031. doi: 10.1016/j.jtha.2023.04.039Nicolai L, Kaiser R, Stark K. Thromboinflammation in long COVID – The elusive key to postinfection sequelae? J Thromb Haemost. 2023;21(8):2020-2031. doi: 10.1016/j.jtha.2023.04.039Wang C, Yu C, Jing H, Wu X, Novakovic VA, Xie R, et al. Long COVID: The nature of thrombotic sequelae determines the necessity of early anticoagulation. Front Cell Infect Microbiol. 2022;12:861703. doi: 10.3389/fcimb.2022.861703Wang C, Yu C, Jing H, Wu X, Novakovic VA, Xie R, et al. Long COVID: The nature of thrombotic sequelae determines the necessity of early anticoagulation. Front Cell Infect Microbiol. 2022;12:861703. doi: 10.3389/fcimb.2022.861703Xiang M, Jing H, Wang C, Novakovic VA, Shi J. Persistent lung injury and prothrombotic state in long COVID. Front Immunol. 2022;13:862522. doi: 10.3389/fimmu.2022.862522Xiang M, Jing H, Wang C, Novakovic VA, Shi J. Persistent lung injury and prothrombotic state in long COVID. Front Immunol. 2022;13:862522. doi: 10.3389/fimmu.2022.862522Gyöngyösi M, Alcaide P, Asselbergs FW, Brundel BJJM, Camici GG, Martins PDC, et al. Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: A joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovasc Res. 2023;119(2):336-356. doi: 10.1093/cvr/cvac115Gyöngyösi M, Alcaide P, Asselbergs FW, Brundel BJJM, Camici GG, Martins PDC, et al. Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: A joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovasc Res. 2023;119(2):336-356. doi: 10.1093/cvr/cvac115Eberhardt N, Noval MG, Kaur R, Amadori L, Gildea M, Sajja S, et al. SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels. Nat Cardiovasc Res. 2023;2(10):899-916. doi: 10.1038/s44161-023-00336-5Eberhardt N, Noval MG, Kaur R, Amadori L, Gildea M, Sajja S, et al. SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels. Nat Cardiovasc Res. 2023;2(10):899-916. doi: 10.1038/s44161-023-00336-5Xiang M, Wu X, Jing H, Novakovic VA, Shi J. The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. Front Cardiovasc Med. 2023;10:1062491. doi: 10.3389/fcvm.2023.1062491Xiang M, Wu X, Jing H, Novakovic VA, Shi J. The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. Front Cardiovasc Med. 2023;10:1062491. doi: 10.3389/fcvm.2023.1062491Baimukhamedov C, Botabekova A, Lessova Z, Abshenov B, Kurmanali N. Osteonecrosis amid the COVID-19 pandemic. Rheumatol Int. 2023;43(7):1377-1378. doi: 10.1007/s00296-023-05332-3Baimukhamedov C, Botabekova A, Lessova Z, Abshenov B, Kurmanali N. Osteonecrosis amid the COVID-19 pandemic. Rheumatol Int. 2023;43(7):1377-1378. doi: 10.1007/s00296-023-05332-3Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-66. doi: 10.1038/s41584-020-0372-xSchrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-66. doi: 10.1038/s41584-020-0372-xDima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: Overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001. doi: 10.1177/1759720X211073001Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: Overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001. doi: 10.1177/1759720X211073001Tripathy S, Dassarma B, Roy S, Chabalala H, Matsabisa MG. A review on possible modes of action of chloroquine/hydroxychloroquine: Repurposing against SAR-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents. 2020;56(2):106028. doi: 10.1016/j.ijantimicag.2020.106028Tripathy S, Dassarma B, Roy S, Chabalala H, Matsabisa MG. A review on possible modes of action of chloroquine/hydroxychloroquine: Repurposing against SAR-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents. 2020;56(2):106028. doi: 10.1016/j.ijantimicag.2020.106028Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ. 2023;380:e069717. doi: 10.1136/bmj-2021-069717Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ. 2023;380:e069717. doi: 10.1136/bmj-2021-069717Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089Schmidt-Tanguy A, Voswinkel J, Henrion D, Subra JF, Loufrani L, Rohmer V, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost. 2013;11(10):1927-1929. doi: 10.1111/jth.12363. PMID: 23902281Schmidt-Tanguy A, Voswinkel J, Henrion D, Subra JF, Loufrani L, Rohmer V, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost. 2013;11(10):1927-1929. doi: 10.1111/jth.12363. PMID: 23902281Schreiber K, Breen K, Parmar K, Rand JH, Wu X-X, Hunt BJ. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology (Oxford). 2018;57(1):120-124. doi: 10.1093/rheumatology/kex378Schreiber K, Breen K, Parmar K, Rand JH, Wu X-X, Hunt BJ. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology (Oxford). 2018;57(1):120-124. doi: 10.1093/rheumatology/kex378Nuri E, Taraborelli M, Andreoli L, Tonello M, Gerosa M, Calligaro A, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res. 2017;65(1):17-24. doi: 10.1007/s12026-016-8812-zNuri E, Taraborelli M, Andreoli L, Tonello M, Gerosa M, Calligaro A, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res. 2017;65(1):17-24. doi: 10.1007/s12026-016-8812-zKravvariti E, Koutsogianni A, Samoli E, Sfikakis PP, Tektonidou MG. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmun Rev. 2020;19(4):102491. doi: 10.1016/j.autrev.2020.102491Kravvariti E, Koutsogianni A, Samoli E, Sfikakis PP, Tektonidou MG. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmun Rev. 2020;19(4):102491. doi: 10.1016/j.autrev.2020.102491Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, et al.; APS ACTION. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus. 2018;27(3):399-406. doi: 10.1177/0961203317724219Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, et al.; APS ACTION. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus. 2018;27(3):399-406. doi: 10.1177/0961203317724219Chighizola CB, Willis R, Maioli G, Sciascia S, Andreoli L, Amengual O, et al. Deciphering the clinical significance of longitudinal antiphospholipid antibody titers. Autoimmun Rev. 2024;23(3):103510. doi: 10.1016/j.autrev.2023.103510Chighizola CB, Willis R, Maioli G, Sciascia S, Andreoli L, Amengual O, et al. Deciphering the clinical significance of longitudinal antiphospholipid antibody titers. Autoimmun Rev. 2024;23(3):103510. doi: 10.1016/j.autrev.2023.103510Infante M, Ricordi C, Fabbri A. Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. J Diabetes. 2020;12(9):659-667. doi: 10.1111/1753-0407.13053Infante M, Ricordi C, Fabbri A. Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. J Diabetes. 2020;12(9):659-667. doi: 10.1111/1753-0407.13053Wondafrash DZ, Desalegn TZ, Yimer EM, Tsige AG, Adamu BA, Zewdie KA. Potential effect of hydroxychloroquine in diabetes mellitus: A systematic review on preclinical and clinical trial studies. J Diabetes Res. 2020;2020:5214751. doi: 10.1155/2020/5214751Wondafrash DZ, Desalegn TZ, Yimer EM, Tsige AG, Adamu BA, Zewdie KA. Potential effect of hydroxychloroquine in diabetes mellitus: A systematic review on preclinical and clinical trial studies. J Diabetes Res. 2020;2020:5214751. doi: 10.1155/2020/5214751Алекберова ЗС, Насонов ЕЛ. Перспективы применения колхицина в медицине: новые данные. Научно-практическая ревматология. 2020;58(2):183-190. doi: 10.14412/1995-4484-2020-183-190Alekberova ZS, Nasonov EL. Prospects for using colchicine in medicine: New evidence. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(2):183-190 (In Russ.) doi: 10.14412/1995-4484-2020-183-190Casey A, Quinn S, McAdam B, Kennedy M, Sheahan R. Colchicine-regeneration of an old drug. Ir J Med Sci. 2023;192(1):115-123. doi: 10.1007/s11845-022-02938-7Casey A, Quinn S, McAdam B, Kennedy M, Sheahan R. Colchicine-regeneration of an old drug. Ir J Med Sci. 2023;192(1):115-123. doi: 10.1007/s11845-022-02938-7Bonaventura A, Vecchié A, Dagna L, Tangianu F, Abbate A, Dentali F. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. Inflamm Res. 2022;71(3):293-307. doi: 10.1007/s00011-022-01540-yBonaventura A, Vecchié A, Dagna L, Tangianu F, Abbate A, Dentali F. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. Inflamm Res. 2022;71(3):293-307. doi: 10.1007/s00011-022-01540-yDrosos AA, Pelechas E, Drossou V, Voulgari PV. Colchicine against SARS-CoV-2 infection: What is the evidence? Rheumatol Ther. 2022;9(2):379-389. doi: 10.1007/s40744-022-00425-0Drosos AA, Pelechas E, Drossou V, Voulgari PV. Colchicine against SARS-CoV-2 infection: What is the evidence? Rheumatol Ther. 2022;9(2):379-389. doi: 10.1007/s40744-022-00425-0Nelson K, Fuster V, Ridker PM. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2023;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055Nelson K, Fuster V, Ridker PM. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2023;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055Ebrahimi F, Hirt J, Schönenberger C, Ewald H, Briel M, Janiaud P, et al. Colchicine for the secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2023;2023(8):CD014808. doi: 10.1002/14651858.CD014808Ebrahimi F, Hirt J, Schönenberger C, Ewald H, Briel M, Janiaud P, et al. Colchicine for the secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2023;2023(8):CD014808. doi: 10.1002/14651858.CD014808Li W, Lin A, Hutton M, Dhaliwal H, Nadel J, Rodor J. Colchicine promotes atherosclerotic plaque stability independently of inflammation. bioRxiv. 2023.10.03.560632. doi: 10.1101/2023.10.03.560632Li W, Lin A, Hutton M, Dhaliwal H, Nadel J, Rodor J. Colchicine promotes atherosclerotic plaque stability independently of inflammation. bioRxiv. 2023.10.03.560632. doi: 10.1101/2023.10.03.560632Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, et al. Colchicine in cardiovascular disease: In-depth review. Circulation. 2022;145(1):61-78. doi: 10.1161/CIRCULATIONAHA.121.056171Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, et al. Colchicine in cardiovascular disease: In-depth review. Circulation. 2022;145(1):61-78. doi: 10.1161/CIRCULATIONAHA.121.056171Furqan MM, Verma BR, Cremer PC, Imazio M, Klein AL. Pericardial diseases in COVID19: a contemporary review. Curr Cardiol Rep. 2021;23(7):90. doi: 10.1007/s11886-021-01519-xFurqan MM, Verma BR, Cremer PC, Imazio M, Klein AL. Pericardial diseases in COVID19: a contemporary review. Curr Cardiol Rep. 2021;23(7):90. doi: 10.1007/s11886-021-01519-xНасонов ЕЛ, Сукмарова ЗН, Попкова ТВ, Белов БС. Проблемы иммунопатологии и перспективы фармакотерапии идиопатического рецидивирующего перикардита: применение ингибитора интерлейкина 1 (Анакинра). Научно-практическая ревматология. 2023;61(1):47-61. doi: 10.47360/1995-4484-2023-47-61Nasonov EL, Sukmarova ZN, Popkova TV, Belov BS. Problems of immunopathology and prospects for pharmacotherapy of idiopathic recurrent pericarditis: Using an interleukin 1 inhibitor (Anakinra). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(1):47-61 (In Russ.) doi: 10.47360/1995-4484-2023-47-61Dini FL, Baldini U, Bytyçi I, Pugliese NR, Bajraktari G, Henein MY. Acute pericarditis as a major clinical manifestation of long COVID-19 syndrome. Int J Cardiol. 2023;374:129-134. doi: 10.1016/j.ijcard.2022.12.019Dini FL, Baldini U, Bytyçi I, Pugliese NR, Bajraktari G, Henein MY. Acute pericarditis as a major clinical manifestation of long COVID-19 syndrome. Int J Cardiol. 2023;374:129-134. doi: 10.1016/j.ijcard.2022.12.019Di Dedda EA, Barison A, Aquaro GD, Ismail TF, Hua A, Mantini C, et al. Cardiac magnetic resonance imaging of myocarditis and pericarditis following COVID-19 vaccination: A multicenter collection of 27 cases. Eur Radiol. 2022;32(7):4352-4360. doi: 10.1007/s00330-022-08566-0Di Dedda EA, Barison A, Aquaro GD, Ismail TF, Hua A, Mantini C, et al. Cardiac magnetic resonance imaging of myocarditis and pericarditis following COVID-19 vaccination: A multicenter collection of 27 cases. Eur Radiol. 2022;32(7):4352-4360. doi: 10.1007/s00330-022-08566-0Buckley BJR, Harrison SL, Fazio-Eynullayeva E, Underhill P, Lane DA, Lip GYH. Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. Eur J Clin Invest. 2021;51(11):e13679. doi: 10.1111/eci.13679Buckley BJR, Harrison SL, Fazio-Eynullayeva E, Underhill P, Lane DA, Lip GYH. Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. Eur J Clin Invest. 2021;51(11):e13679. doi: 10.1111/eci.13679Gao J, Feng L, Li Y, Lowe S, Guo Z, Bentley R, et al. A systematic review and meta-analysis of the association between SARSCoV-2 vaccination and myocarditis or pericarditis. Am J Prev Med. 2023;64(2):275-284. doi: 10.1016/j.amepre.2022.09.002Gao J, Feng L, Li Y, Lowe S, Guo Z, Bentley R, et al. A systematic review and meta-analysis of the association between SARSCoV-2 vaccination and myocarditis or pericarditis. Am J Prev Med. 2023;64(2):275-284. doi: 10.1016/j.amepre.2022.09.002Li P, Shi A, Lu X, Li C, Cai P, Teng C, et al. Incidence and impact of acute pericarditis in hospitalized patients with COVID-19. J Am Heart Assoc. 2023;12(20):e028970. doi: 10.1161/JAHA.122.028970Li P, Shi A, Lu X, Li C, Cai P, Teng C, et al. Incidence and impact of acute pericarditis in hospitalized patients with COVID-19. J Am Heart Assoc. 2023;12(20):e028970. doi: 10.1161/JAHA.122.028970Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-810. doi: 10.1001/jamacardio.2020.0950Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-810. doi: 10.1001/jamacardio.2020.0950Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745-2760. doi: 10.1093/eurheartj/ehab221Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745-2760. doi: 10.1093/eurheartj/ehab221Yeh JJ, Hung TW, Lin CL, Chen TT, Liw PX, Yu YL, et al. Colchicine is a weapon for managing the heart disease among interstitial lung disease with viral infection: Have we found the Holy Grail? Front Cardiovasc Med. 2022;9:925211. doi: 10.3389/fcvm.2022.925211Yeh JJ, Hung TW, Lin CL, Chen TT, Liw PX, Yu YL, et al. Colchicine is a weapon for managing the heart disease among interstitial lung disease with viral infection: Have we found the Holy Grail? Front Cardiovasc Med. 2022;9:925211. doi: 10.3389/fcvm.2022.925211Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: What have we learned? BioDrugs. 2024;38:61-71. doi: 10.1007/s40259-023-00634-1Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: What have we learned? BioDrugs. 2024;38:61-71. doi: 10.1007/s40259-023-00634-1Kishimoto T, Kang S. IL-6 revisited: From rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu Rev Immunol. 2022;40:323-348. doi: 10.1146/annurev-immunol-101220-023458Kishimoto T, Kang S. IL-6 revisited: From rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu Rev Immunol. 2022;40:323-348. doi: 10.1146/annurev-immunol-101220-023458Feist E, Nasonov E. Interleukin 6 inhibition in rheumatoid arthritis: Highlight on olokizumab. Rheumatology. 2023;2(1):17-27. doi: 10.17925/RMD.2023.2.1.17Feist E, Nasonov E. Interleukin 6 inhibition in rheumatoid arthritis: Highlight on olokizumab. Rheumatology. 2023;2(1):17-27. doi: 10.17925/RMD.2023.2.1.17Насонов ЕЛ. Иммунопатология и иммунофармакотерапия коронавирусной болезни 2019 (COVID-19): Фокус на интерлейкин 6. Научно-практическая ревматология. 2020;58(3):245-261. doi: 10.14412/1995-4484-2020-245-261Nasonov EL. Immunopathology and immunopharmacotherapy of coronavirus disease 2019 (COVID-19): Focus on interleukin 6. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(3):245-261 (In Russ.) doi: 10.14412/1995-4484-2020-245-261Nasonov E, Samsonov M. The role of interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi: 10.1016/j.biopha.2020.110698Nasonov E, Samsonov M. The role of interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi: 10.1016/j.biopha.2020.110698Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5Yin JX, Agbana YL, Sun ZS, Fei SW, Zhao HQ, Zhou XN, et al. Increased interleukin-6 is associated with long COVID-19: A systematic review and meta-analysis. Infect Dis Poverty. 2023;12(1):43. doi: 10.1186/s40249-023-01086-zYin JX, Agbana YL, Sun ZS, Fei SW, Zhao HQ, Zhou XN, et al. Increased interleukin-6 is associated with long COVID-19: A systematic review and meta-analysis. Infect Dis Poverty. 2023;12(1):43. doi: 10.1186/s40249-023-01086-zEspín E, Yang C, Shannon CP, Assadian S, He D, Tebbutt SJ. Cellular and molecular biomarkers of long COVID: A scoping review. EBioMedicine. 2023;91:104552. doi: 10.1016/j.ebiom.2023.104552Espín E, Yang C, Shannon CP, Assadian S, He D, Tebbutt SJ. Cellular and molecular biomarkers of long COVID: A scoping review. EBioMedicine. 2023;91:104552. doi: 10.1016/j.ebiom.2023.104552Schultheiß C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022;3(6):100663. doi: 10.1016/j.xcrm.2022.100663Schultheiß C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022;3(6):100663. doi: 10.1016/j.xcrm.2022.100663Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARSCoV-2 infection. Nat Immunol. 2022;23(2):210-216. doi: 10.1038/s41590-021-01113-xPhetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARSCoV-2 infection. Nat Immunol. 2022;23(2):210-216. doi: 10.1038/s41590-021-01113-xSunzini F, Schrepf A, Clauw DJ, Basu N. The biology of pain: Through the rheumatology lens. Arthritis Rheumatol. 2023;75(5):650-660. doi: 10.1002/art.42429.Sunzini F, Schrepf A, Clauw DJ, Basu N. The biology of pain: Through the rheumatology lens. Arthritis Rheumatol. 2023;75(5):650-660. doi: 10.1002/art.42429.Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин 6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318-327. doi: 10.14412/1995-4484-2019-318-327Lisitsyna TA, Veltishchev DYu, Lila AM, Nasonov EL. Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(3):318-327 (In Russ.) doi: 10.14412/1995-4484-2019-318-327Atzeni F, Nucera V, Masala IF, Sarzi-Puttini P, Bonitta G. Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab. Pharmacol Res. 2019;149:104402. doi: 10.1016/j.phrs.2019.104402Atzeni F, Nucera V, Masala IF, Sarzi-Puttini P, Bonitta G. Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab. Pharmacol Res. 2019;149:104402. doi: 10.1016/j.phrs.2019.104402Zhou YQ, Liu Z, Liu ZH, Chen SP, Li M, Shahveranov A, et al. Interleukin-6: An emerging regulator of pathological pain. J Neuroinflammation. 2016;13(1):141. doi: 10.1186/s12974-016-0607-6Zhou YQ, Liu Z, Liu ZH, Chen SP, Li M, Shahveranov A, et al. Interleukin-6: An emerging regulator of pathological pain. J Neuroinflammation. 2016;13(1):141. doi: 10.1186/s12974-016-0607-6Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. 2021;131:105295. doi: 10.1016/j.psyneuen.2021.105295Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. 2021;131:105295. doi: 10.1016/j.psyneuen.2021.105295PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: A prospective observational study. Lancet Respir Med. 2022;10(8):761-775. doi: 10.1016/S2213-2600(22)00127-8PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: A prospective observational study. Lancet Respir Med. 2022;10(8):761-775. doi: 10.1016/S2213-2600(22)00127-8Visvabharathy L, Orban ZS, Koralnik IJ. Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence. Front Med (Lausanne). 2022;9:1003103. doi: 10.3389/fmed.2022.1003103Visvabharathy L, Orban ZS, Koralnik IJ. Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence. Front Med (Lausanne). 2022;9:1003103. doi: 10.3389/fmed.2022.1003103Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18(1):58-68. doi: 10.1038/s41569-020-0431-7Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18(1):58-68. doi: 10.1038/s41569-020-0431-7Su JH, Luo MY, Liang N, Gong SX, Chen W, Huang WQ, et al. Interleukin-6: A novel target for cardio-cerebrovascular diseases. Front Pharmacol. 2021;12:745061. doi: 10.3389/fphar.2021.745061Su JH, Luo MY, Liang N, Gong SX, Chen W, Huang WQ, et al. Interleukin-6: A novel target for cardio-cerebrovascular diseases. Front Pharmacol. 2021;12:745061. doi: 10.3389/fphar.2021.745061Libby P. Targeting inflammatory pathways in cardiovascular disease: The inflammasome, interleukin-1, interleukin-6 and beyond. Cells. 2021;10(4):951. doi: 10.3390/cells10040951Libby P. Targeting inflammatory pathways in cardiovascular disease: The inflammasome, interleukin-1, interleukin-6 and beyond. Cells. 2021;10(4):951. doi: 10.3390/cells10040951Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128(11):1728-1746. doi: 10.1161/CIRCRESAHA.121.319077Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128(11):1728-1746. doi: 10.1161/CIRCRESAHA.121.319077Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al.; RESCUE Investigators. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al.; RESCUE Investigators. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023;82(4):279-285. doi: 10.1016/j.jjcc.2023.05.006Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023;82(4):279-285. doi: 10.1016/j.jjcc.2023.05.006Toraldo DM, Satriano F, Rollo R, Verdastro G, Imbriani G, Rizzo E, et al. COVID-19 IgG/IgM patterns, early IL-6 elevation and long-term radiological sequelae in 75 patients hospitalized due to interstitial pneumonia followed up from 3 to 12 months. PLoS One. 2022;17(2):e0262911. doi: 10.1371/journal.pone.0262911Toraldo DM, Satriano F, Rollo R, Verdastro G, Imbriani G, Rizzo E, et al. COVID-19 IgG/IgM patterns, early IL-6 elevation and long-term radiological sequelae in 75 patients hospitalized due to interstitial pneumonia followed up from 3 to 12 months. PLoS One. 2022;17(2):e0262911. doi: 10.1371/journal.pone.0262911Lee JH, Jang JH, Park JH, Jang HJ, Park CS, Lee S, et al. The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases. PLoS One. 2021;16(7):e0255365. doi: 10.1371/journal.pone.0255365Lee JH, Jang JH, Park JH, Jang HJ, Park CS, Lee S, et al. The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases. PLoS One. 2021;16(7):e0255365. doi: 10.1371/journal.pone.0255365Ma C, Meng K, Shi S, Zhao T, Chen S, Zhou X, et al. Clinical significance of interleukin-6, total bilirubin, CD3+CD4+T cells counts in the acute exacerbation of connective tissue diseaseassociated interstitial lung disease: A cross-sectional study. Eur J Med Res. 2023;28(1):393. doi: 10.1186/s40001-023-01384-0Ma C, Meng K, Shi S, Zhao T, Chen S, Zhou X, et al. Clinical significance of interleukin-6, total bilirubin, CD3+CD4+T cells counts in the acute exacerbation of connective tissue diseaseassociated interstitial lung disease: A cross-sectional study. Eur J Med Res. 2023;28(1):393. doi: 10.1186/s40001-023-01384-0Насонов ЕЛ, Ананьева ЛП, Авдеев СН. Интерстициальные заболевания легких при ревматоидном артрите: мультидисциплинарная проблема ревматологии и пульмонологии. Научно-практическая ревматология. 2022;60(6):517-534. doi: 10.47360/1995-4484-2022-1Nasonov EL, Ananyeva LP, Avdeev SN. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(6):517-534 (In Russ.) doi: 10.47360/1995-4484-2022-1Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M,Raghu G, et al. Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: Open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med. 2022;205(6):674-684. doi: 10.1164/rccm.202103-0714OCKhanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M,Raghu G, et al. Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: Open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med. 2022;205(6):674-684. doi: 10.1164/rccm.202103-0714OCCutolo M, Smith V, Paolino S, Gotelli E. Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19. Nat Rev Rheumatol. 2023;19(5):265-287. doi: 10.1038/s41584-023-00944-2Cutolo M, Smith V, Paolino S, Gotelli E. Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19. Nat Rev Rheumatol. 2023;19(5):265-287. doi: 10.1038/s41584-023-00944-2Dissanayake HA, de Silva NL, Sumanatilleke M, de Silva SDN, Gamage KKK, Dematapitiya C, et al. Prognostic and therapeutic role of vitamin D in COVID-19: Systematic review and metaanalysis. J Clin Endocrinol Metab. 2022;107(5):1484-1502. doi: 10.1210/clinem/dgab892Dissanayake HA, de Silva NL, Sumanatilleke M, de Silva SDN, Gamage KKK, Dematapitiya C, et al. Prognostic and therapeutic role of vitamin D in COVID-19: Systematic review and metaanalysis. J Clin Endocrinol Metab. 2022;107(5):1484-1502. doi: 10.1210/clinem/dgab892Oristrell J, Oliva JC, Subirana I, Casado E, Domínguez D, Toloba A, et al. Association of calcitriol supplementation with reduced COVID-19 mortality in patients with chronic kidney disease: A population-based study. Biomedicines. 2021;9(5):509. doi: 10.3390/biomedicines9050509Oristrell J, Oliva JC, Subirana I, Casado E, Domínguez D, Toloba A, et al. Association of calcitriol supplementation with reduced COVID-19 mortality in patients with chronic kidney disease: A population-based study. Biomedicines. 2021;9(5):509. doi: 10.3390/biomedicines9050509Villasis-Keever MA, López-Alarcón MG, Miranda-Novales G, Zurita-Cruz JN, Barrada-Vázquez AS, González-Ibarra J, et al. Efficacy and safety of vitamin D supplementation to prevent COVID-19 in frontline healthcare workers. A randomized clinical trial. Arch Med Res. 2022;53(4):423-430. doi: 10.1016/j.arcmed.2022.04.003Villasis-Keever MA, López-Alarcón MG, Miranda-Novales G, Zurita-Cruz JN, Barrada-Vázquez AS, González-Ibarra J, et al. Efficacy and safety of vitamin D supplementation to prevent COVID-19 in frontline healthcare workers. A randomized clinical trial. Arch Med Res. 2022;53(4):423-430. doi: 10.1016/j.arcmed.2022.04.003Hahn J, Cook NR, Alexander EK, Friedman S, Walter J, Bubes V, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452. doi: 10.1136/bmj-2021-066452Hahn J, Cook NR, Alexander EK, Friedman S, Walter J, Bubes V, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452. doi: 10.1136/bmj-2021-066452Achleitner M, Steenblock C, Dänhardt J, Jarzebska N, Kardashi R, Kanczkowski W, et al. Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Mol Psychiatry. 2023;28(7):2872-2877. doi: 10.1038/s41380-023-02084-1Achleitner M, Steenblock C, Dänhardt J, Jarzebska N, Kardashi R, Kanczkowski W, et al. Clinical improvement of LongCOVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Mol Psychiatry. 2023;28(7):2872-2877. doi: 10.1038/s41380-023-02084-1Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 5. Arthritis Rheumatol. 2023;75(1):E1-E16. doi: 10.1002/art.42372Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 5. Arthritis Rheumatol. 2023;75(1):E1-E16. doi: 10.1002/art.42372Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-254. doi: 10.47360/1995-4484-2021-239-254Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the Association of Rheumatologists of Russia. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(3):239-254 (In Russ.) doi: 10.47360/1995-4484-2021-239-254van Sleen Y, van der Geest KSM, Huckriede ALW, van Baarle D, Brouwer E. Effect of DMARDs on the immunogenicity of vaccines. Nat Rev Rheumatol. 2023;19(9):560-575. doi: 10.1038/s41584-023-00992-8van Sleen Y, van der Geest KSM, Huckriede ALW, van Baarle D, Brouwer E. Effect of DMARDs on the immunogenicity of vaccines. Nat Rev Rheumatol. 2023;19(9):560-575. doi: 10.1038/s41584-023-00992-8Hansen N. Psychiatric symptoms in acute and persisting forms of COVID-19 associated with neural autoantibodies. Antibodies (Basel). 2023;12(3):49. doi: 10.3390/antib12030049Hansen N. Psychiatric symptoms in acute and persisting forms of COVID-19 associated with neural autoantibodies. Antibodies (Basel). 2023;12(3):49. doi: 10.3390/antib12030049Seibert FS, Stervbo U, Wiemers L, Skrzypczyk S, Hogeweg M, Bertram S, et al. Severity of neurological long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors. Autoimmun Rev. 2023;22(11):103445. doi: 10.1016/j.autrev.2023.103445Seibert FS, Stervbo U, Wiemers L, Skrzypczyk S, Hogeweg M, Bertram S, et al. Severity of neurological long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors. Autoimmun Rev. 2023;22(11):103445. doi: 10.1016/j.autrev.2023.103445Feng A, Yang EY, Moore AR, Dhingra S, Chang SE, Yin X, et al. Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness. JCI Insight. 2023;8(3):e163150. doi: 10.1172/jci.insight.163150Feng A, Yang EY, Moore AR, Dhingra S, Chang SE, Yin X, et al. Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness. JCI Insight. 2023;8(3):e163150. doi: 10.1172/jci.insight.163150Bodansky A, Wang CY, Saxena A, Mitchell A, Kung AF, Takahashi S, et al. Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients. JCI Insight. 2023;8(11):e169515. doi: 10.1172/jci.insight.169515Bodansky A, Wang CY, Saxena A, Mitchell A, Kung AF, Takahashi S, et al. Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients. JCI Insight. 2023;8(11):e169515. doi: 10.1172/jci.insight.169515Jiang W, Johnson D, Adekunle R, Heather H, Xu W, Cong X, et al. COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity. J Med Virol. 2023;95(1):e28134. doi: 10.1002/jmv.28134Jiang W, Johnson D, Adekunle R, Heather H, Xu W, Cong X, et al. COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity. J Med Virol. 2023;95(1):e28134. doi: 10.1002/jmv.28134Lebedin M, García CV, Spatt L, Ratswohl C, Thibeault C, Ostendorf L, et al. Discriminating promiscuous from target-specific autoantibodies in COVID-19. Eur J Immunol. 2023;53(5):e2250210. doi: 10.1002/eji.202250210Lebedin M, García CV, Spatt L, Ratswohl C, Thibeault C, Ostendorf L, et al. Discriminating promiscuous from target-specific autoantibodies in COVID-19. Eur J Immunol. 2023;53(5):e2250210. doi: 10.1002/eji.202250210Skevaki C, Wesemann DR. Antibody repertoire and autoimmunity. J Allergy Clin Immunol. 2023;151(4):898-900. doi: 10.1016/j.jaci.2023.0Skevaki C, Wesemann DR. Antibody repertoire and autoimmunity. J Allergy Clin Immunol. 2023;151(4):898-900. doi: 10.1016/j.jaci.2023.0Carlton LH, McGregor R, Moreland NJ. Human antibody profiling technologies for autoimmune disease. Immunol Res. 2023;71(4):516-527. doi: 10.1007/s12026-023-09362-8Carlton LH, McGregor R, Moreland NJ. Human antibody profiling technologies for autoimmune disease. Immunol Res. 2023;71(4):516-527. doi: 10.1007/s12026-023-09362-8Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, et al. Antibody validation. Biotechniques. 2010;48(3):197-209. doi: 10.2144/000113382Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, et al. Antibody validation. Biotechniques. 2010;48(3):197-209. doi: 10.2144/000113382Sack U, Bossuyt X, Andreeva H, Antal-Szalmás P, Bizzaro N, Bogdanos D, et al.; European Autoimmunity Standardisation Initiative. Quality and best practice in medical laboratories: Specific requests for autoimmunity testing. Auto Immun Highlights. 2020;11(1):12. doi: 10.1186/s13317-020-00134-0Sack U, Bossuyt X, Andreeva H, Antal-Szalmás P, Bizzaro N, Bogdanos D, et al.; European Autoimmunity Standardisation Initiative. Quality and best practice in medical laboratories: Specific requests for autoimmunity testing. Auto Immun Highlights. 2020;11(1):12. doi: 10.1186/s13317-020-00134-0Fritzler MJ, Choi MY, Satoh M, Mahler M. Autoantibody discovery, assay development and adoption: Death valley, the sea of survival and beyond. Front Immunol. 2021;12:679613. doi: 10.3389/fimmu.2021.679613Fritzler MJ, Choi MY, Satoh M, Mahler M. Autoantibody discovery, assay development and adoption: Death valley, the sea of survival and beyond. Front Immunol. 2021;12:679613. doi: 10.3389/fimmu.2021.679613Treger RS, Fink SL. Beyond titer: Expanding the scope of clinical autoantibody testing. J Appl Lab Med. 2022;7(1):99-113. doi: 10.1093/jalm/jfab123Treger RS, Fink SL. Beyond titer: Expanding the scope of clinical autoantibody testing. J Appl Lab Med. 2022;7(1):99-113. doi: 10.1093/jalm/jfab123Seeling M, Brückner C, Nimmerjahn F. Differential antibody glycosylation in autoimmunity: Sweet biomarker or modulator of disease activity? Nat Rev Rheumatol. 2017;13(10):621-630. doi: 10.1038/nrrheum.2017.146Seeling M, Brückner C, Nimmerjahn F. Differential antibody glycosylation in autoimmunity: Sweet biomarker or modulator of disease activity? Nat Rev Rheumatol. 2017;13(10):621-630. doi: 10.1038/nrrheum.2017.146Simpson S, Kaufmann MC, Glozman V, Chakrabarti A. Disease X: Accelerating the development of medical countermeasures for the next pandemic. Lancet Infect Dis. 2020;20(5):e108-e115. doi: 10.1016/S1473-3099(20)30123-7Simpson S, Kaufmann MC, Glozman V, Chakrabarti A. Disease X: Accelerating the development of medical countermeasures for the next pandemic. Lancet Infect Dis. 2020;20(5):e108-e115. doi: 10.1016/S1473-3099(20)30123-7

The authors declare that there are no conflicts of interest present.